| 3244 | Vojtech Huser | Identification of Research Common Data Elements in HIV/AIDS | National Library of Medicine/NIH | AbbVie, Pfizer Inc. |
| 3246 | Dawn Farrell | Cochrane Review: Interventions for fatigue in inflammatory bowel disease | Institute of Technology Tralee | AbbVie |
| 3270 | Mirjana Stanic Benic | The impact of biological interventions on health‐related quality of life in adults with Crohn's disease | UHC Rijeka | AbbVie, Biogen |
| 3287 | Robert Alexander | Identification of biomarkers associated with specific sleep variables | Takeda | GlaxoSmithKline |
| 3288 | Marc-Antoine Sparfel | MIDRA : influence of demographic and environmental factors on anti- tumor necrosis factor efficacy in rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials | Tours Hospital | AbbVie, Pfizer Inc., UCB |
| 3320 | John Frew | Analysis of Outcome Measures in Hidradenitis Suppurativa | Rockefeller University | AbbVie |
| 3321 | Ewa Olech | Optimization of lupus trial design based on entry variables | IQVIA | GlaxoSmithKline |
| 3328 | Klaus Gottlieb | Mapping of components of the complete blood count and comprehensive metabolic profile to disease-specific clinical and endoscopy endpoints in phase 2 and 3 clinical trials of ulcerative colitis and Crohn’s disease | Eli Lilly USA | Takeda |
| 3361 | Gustav Nilsonne | Interleukin-6 distribution in plasma/serum | Karolinska Institutet | GlaxoSmithKline, AbbVie |
| 3369 | Michael Ward | Predicting Treatment Response to Tumor Necrosis Factor Inhibitors in patients with ankylosing spondylitis | NIH | AbbVie, Pfizer Inc. |
| 3762 | Lin Wang | The relative efficacy and safety of apalutamide, enzalutamide, abiraterone, and darolutamide for nonmetastatic castration-resistant prostate cancer | Johns Hopkins School of Public Health, Johns Hopkins Hospital | Project Data Sphere, LLC, Pfizer Inc. |
| 3876 | Changyu Shen | Risk and Benefit Stratification of Treatment Effects in Patients with Atrial Fibrillation | Beth Israel Deaconess Medical Center, | Daiichi Sankyo, Inc., Boehringer Ingelheim |
| 4036 | Akira Kimata | Dabigatran Integrated Analysis | Department of Cardiology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan | Boehringer Ingelheim |
| 4037 | Karl Peace | Assessment of Matching Methods for Causal Analysis | Jiann-Ping Hsu College of Public Health, Georgia Southern University | Boehringer Ingelheim |
| 4039 | claire daien | Non-MTX-csDMARDs versus MTX in combination with tofacitinib: a post hoc analysis | CHU lapeyronie | Pfizer Inc. |
| 4041 | Vivek Rudrapatna | Enhancing inference from real-world data using externally-derived missing data models: a pilot study of Ulcerative Colitis | University of California, San Francisco | Takeda, AbbVie, Johnson & Johnson |
| 4043 | Janneke van der Woude | Tofacitinib ulcerative colitis | Dept. of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, The Netherlands | Pfizer Inc. |
| 4047 | Miriam Oron | biological drugs data analysis | Skintelligence ltd. | ImmPort (a data-sharing platform funded by the National Institutes of Health) |
| 4113 | Lesley Inker | Chronic Kidney Disease Epidemiology – Clinical Trials Consortium (CKD-EPI CT) | Division of Neprology, Tufts Medical Center | GlaxoSmithKline, Takeda |
| 4115 | Amir Mahabadi | Impact of statin therapy on coronary artery calcification volume and density – A meta-analysis of randomized controlled trials | University Hospital Essen, West German Heart and Vascular Center, Department of Cardiology and Vascular Medicine | Pfizer Inc. |
| 4116 | Sharon Strauss | Comparative safety and effectiveness of cognitive enhancers for Alzheimer's dementia: a systematic review and individual patient data network meta-analysis | St. Michael’s Hospital | AbbVie |
| 4117 | John Frew | Predictors of Treatment Response, Adverse Events, Changes in Anaemia status and Assessment of Lesion Count Variability in Hidradenitis Suppurativa | Rockefeller University | AbbVie |
| 4118 | J. David Spence | On-Treatment analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial | Western University, London, ON, Canada | Pfizer Inc. |
| 4120 | Merryn Voysey | The immunogenicity and sero-efficacy of pneumococcal vaccines | Oxford Vaccine Group, University of Oxford | Pfizer Inc. |
| 4121 | Frederikus Klok | Performance of the AF-adapted VTE-BLEED score for predicting major bleeding in patients with atrial fibrillation: a post-hoc analysis of the ENGAGE-AF TIMI-48 Study | Leiden University Medical Center | Daiichi Sankyo, Inc. |
| 4275 | Lisa Stamp | Serum urate as a biomarker in gout: Protocol for individual patient data analysis for OMERACT 2020 | University of Otago, Christchurch | Takeda |
| 4278 | Jennifer Quint | Withdrawing inhaled corticosteroid (ICS) treatment in people with COPD: a real world study | Imperial College London | Boehringer Ingelheim |
| 4316 | Martin Okun | Geospatial and Seasonal Variation in Psoriasis Severity: Analysis of Placebo Response Data from Phase 3 placebo-controlled trials in moderate-severe psoriasis | Fort HealthCare | AbbVie |
| 4319 | Maria Alice Franzoi | Clinical implications of body mass index and weight in metastatic breast cancer patients receiving abemaciclib. A combined individual patient level data sub-analysis of MONARCH 2 and MONARCH 3 trials. | Jules Bordet Institut | Lilly |
| 4324 | Peng Xie | Comparative efficacy and tolerability of new-generation antidepressants for major depressive disorder in children and adolescents: an individual patient data meta-analysis | Institute of Neuroscience, Chongqing Medical University, 1 Yixueyuan Road, Yuzhong District Chongqing, china | Lilly, GlaxoSmithKline, Pfizer Inc. |
| 4326 | John Markman | Phenotypic Characterization of Chronic Neuropathic Pain Following Post-Traumatic and Post-Surgical Injury | University of Rochester | Pfizer Inc. |
| 4327 | Michael Szarek | Analysis of Total Events and Hospitalizations in the SPARCL Study | SUNY Downstate Medical Center | Pfizer Inc. |
| 4329 | Shomron Ben-Horin | Efficacy of biologic drugs in short-duration versus long-duration inflammatory bowel disease: A systematic review and an individual-patient level meta-analysis of randomized controlled trials - revised | Sheba Medical Center, Tel- Aviv University, Israel & Sun Yatsen 1st affiliated Hospital, Guangzhou China | Takeda, Biogen, AbbVie, UCB, Johnson & Johnson |
| 4330 | Laure Gossec | Domains of health important for Rheumatoid Arthritis patients can be assessed separately: Reliability and Responsiveness of the Rheumatoid Arthritis Impact of Disease Score - 7 items (RAID.7i) | Sorbonne Université, Paris, France | Pfizer Inc. |
| 4352 | Stefano Barco | Differential effects of long-term treatment with warfarin vs. edoxaban on blood count parameters. A parallel posthoc analysis of the Hokusai VTE and Engage AF-TIMI-48 trials | University Medical Center Mainz; Clinic for Angiology Zürich | Daiichi Sankyo, Inc. |
| 4540 | Chris Gale | Efficacy and safety of edoxaban versus warfarin in patients with atrial fibrillation and frailty: insights from the ENGAGE AF-TIMI 48 trial | University of Leeds | Daiichi Sankyo, Inc. |
| 4541 | C Elizabeth Caldon | Therapeutic targeting of dual CDK4/6 inhibitor and endocrine resistant breast cancer | Garvan Institute of Medical Research | Pfizer Inc. |
| 4913 | Susan Halabi | Surrogate Endpoints of Overall Survival in Non-Metastatic Renal Clear Cell Carcinoma | Duke University | Project Data Sphere, LLC, Pfizer Inc. |
| 4915 | Rachel Tomko | Predicting Individuals' Probability of Response to Smoking Cessation Pharmacotherapy | Medical University of South Carolina | Pfizer Inc. |
| 4917 | Andrea Cipriani | Choosing the Right Antidepressant for Depressive Disorder in Adults: Individual Patient Data Network Meta-Analysis | University of Oxford | Lilly, GlaxoSmithKline, Lundbeck |
| 4918 | Nina Hilkens | Blood pressure variability and cognitive decline | Radboudumc Nijmegen | Boehringer Ingelheim |
| 4919 | Hendrik Jan Guchelaar | Effect of digoxin on survival outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors | Leiden University Medical Center (LUMC) | Pfizer Inc. |
| 4920 | Gustavo Turecki | Predicting Treatment Efficacy in Individuals with Major Depression -- Deep Neural Networks for Physiological Patient Parameters | Douglas Mental Health University Institute | Pfizer Inc. |
| 4921 | Tim Brümmendorf | Entropy – based Biomarkers for individualized response on Bosutinib treatment in chronic phase CML - Brummendorf | University Hospital Aachen | Pfizer Inc. |
| 4922 | Diane van der Woude | Effect of rheumatoid factor and anticitrullinated peptide antibody on the efficacy of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis | Leiden University Medical Center | Pfizer Inc., AbbVie |
| 4926 | Eva-Maria Gamper | Comparison of the EORTC QLU-C10D (a cancer-specific utility instrument) with generic utility instruments and development of a comprehensive manual for its use | Medical University Innsbruck | Boehringer Ingelheim |
| 4931 | Siddharth Singh | Early changes in inflammatory biomarkers and long-term outcomes in patients with IBD: A pooled post-hoc analyses of clinical trials | University of California San Diego | AbbVie, Takeda |
| 4933 | Hongxia Wang | PALOMA-2 Data Request for Biomarker Analysis | Department of Oncology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Pfizer Inc. |
| 4949 | Vivek Rudrapatna | Efficacy of Crohn's Disease Treatment Stratified by Disease Phenotype | University of California San Francisco | AbbVie, Takeda, Johnson & Johnson, Biogen, UCB |
| 4950 | John "Devin" Peipert | Justification of PROMIS (FACIT) Fatigue Short Form 10a scale for FDA Drug Development Tool Qualification in Rheumatoid Arthritis | Northwestern University | AbbVie |
| 5073 | Philip Robinson | Assessment of treatment outcome with etanercept in nraxSpA
by baseline CRP | University of Queensland | Pfizer Inc. |
| 5074 | Sebastian Zundler | Evaluation of the relationship between vedolizumab peripheral blood serum level at week 6 and binary clinical outcomes at week 10/14 in ulcerative colitis and Crohn's disease - meta-analysis | University Hospital Erlangen, Department of Medicine 1 | Takeda |
| 5079 | Maureen Dubreuil | Clinical and MRI predictors of Clinical Response in Axial Spondyloarthritis | Boston University School of Medicine | AbbVie |
| 5080 | Joel Skaistis | ABC-EBUS | Beaumont Health | Boehringer Ingelheim |
| 5086 | Junko Takeshita | A Systematic Review to Describe the Demographic Diversity of Dermatologic Clinical Trial Participants for Common Dermatologic Diseases | University of Pennsylvania | Lilly, AbbVie, Regeneron |
| 5095 | Mathilde Nijkeuter | Assessing bleeding risk in patients with cancer-associated thrombosis | University Medical Center Utrecht | Daiichi Sankyo, Inc. |
| 5096 | Joo Sang Lee | Harnessing genetic interactions to advance precision cancer medicine | Samsung Medical Center, South Korea | Tempus AI, Inc. |
| 5098 | Christopher Baethge | (S)SNRI dose response realtionship | Department of Psychiatry University of Cologne Medical School | Lilly |
| 5099 | Jorge Hernando | Impact of gender on multikinase inhibitors (MKIs) toxicity in patients (pts) with advanced pancreatic and gastrointestinal neuroendocrine tumors | Vall d´Hebron University Hospital | Pfizer Inc. |
| 5163 | Susan Bates, MD | Assessing the tumor growth and decay rates in patients with pancreatic cancer treated with Gemcitabine/Abraxane: Comparing real world data with clinical trial data | Columbia University Medical Center | Celgene Corporation |
| 5165 | Byeongzu Ghang | Reanalysis of CARES study to investigate the incidence of cardiovascular events and death after initiation and discontinuation of allopurinol and febuxostat | Division of Rheumatology, Jeju National University School of Medicine, Jeju National University Hospital, Jeju, Republic of Korea | Takeda |
| 5166 | Thomas Metkus | Severe sepsis in the cardiac intensive care unit: management strategies and outcomes | Johns Hopkins University School of Medicine | Lilly |
| 5207 | Fasihul Khan | A systematic review and individual patient data meta-analysis of physiological biomarkers in idiopathic pulmonary fibrosis | University of Nottingham, UK | Boehringer Ingelheim, Johnson & Johnson, BioLINCC (a data-sharing platform funded by the National Institutes of Health), Roche |
| 5209 | Bruce Perkins | TRIAL-INFORMED DKA MITIGATION EDUCATIONAL TOOL: THE TORONTO-MICHIGAN PATIENT-PROVIDER COLLABORATIVE | Sinai Health System, University of Toronto | Boehringer Ingelheim |
| 5276 | Yan Luo | Predicting the Treatment Response of Certolizumab for Individual Patients with Rheumatoid Arthritis: An Individual Participant Data Meta-Analysis - Luo | Kyoto University | UCB |
| 5290 | Ashley Hopkins | Predictors of therapeutic and adverse effects of medicines used in the treatment of GI cancers. | Flinders University | Lilly, Roche, Boehringer Ingelheim, GlaxoSmithKline |
| 5291 | Sarah Nevitt | Antiepileptic drug monotherapy for epilepsy: an updated Cochrane review and individual participant data network meta-analysis | Department of Biostatistics, University of Liverpool, United Kingdom | UCB |
| 5292 | Désirée van der Heijde | Measurement properties of the instruments used in the outcome assessment of axial spondyloarthritis | Leiden University Medical Center | UCB |
| 5294 | Daniel Caldeira | The clinical impact of dabigratran in patients with non-valvular atrial fibrillation who had a fall or head injury: a retrospective analysis of RE-LY | CCUL - Faculdade de Medicina da Universidade de Lisboa | Boehringer Ingelheim |
| 5325 | Daniel Goldenholz | Retrospective analysis of placebo arm data in clinical epilepsy trials -Goldenholz | Beth Israel Deaconess Medical Center, Harvard Medical School | UCB, GlaxoSmithKline |
| 5330 | Laura Bonnett | Modelling seizure rates within clinical trials of antiepileptic drugs - Bonnett | University of Liverpool | UCB |
| 5352 | Elena Myasoedova | Individualized Prediction of Treatment Response to Methotrexate in Patients with Rheumatoid Arthritis: A Machine Learning Approach - Myasoedova | Mayo Clinic | UCB, Roche |
| 5435 | Matthew Gilbert | Effect of Albiglutide on Cardiovascular Outcomes in Older Adults | Larner College of Medicine at The University of Vermont | GlaxoSmithKline |
| 5436 | Adrian Wagg | A pooled analysis of the efficacy and tolerability of tolterodine for the treatment of Overactive Bladder (OAB) in patients over the age of 65 years of age
| University of Alberta | Pfizer Inc. |
| 5456 | Ramona Belfiore-Oshan | Validation of a Model-based Clinical Trial Simulation Tool to Optimize Clinical Trial Design of Studies to Investigate Efficacy of Potential Therapies for Duchenne Muscular Dystrophy | Critical Path Institute | Cure Duchenne |
| 5483 | David McAllister | Heterogeneity in relative treatment efficacy by age, sex, socioeconomic status and comorbidity (McAllister) | University of Glasgow | Boehringer Ingelheim, Takeda, UCB, Lilly, Roche |
| 5567 | Neeraj Narula | Endoscopic Healing Predictors | McMaster University | AbbVie |
| 5812 | Yougen Wu | Development and validation of nomograms for predicting efficacy and toxicity in cancer patients treated with immune checkpoint inhibitors | The Fifth People's Hospital of Shanghai, Fudan University, Shanghai, China | Roche |
| 5813 | Phillip Garfin | Effectiveness of cytotoxic chemotherapy for the treatment metastatic breast cancer subtypes (Garfin 11387) | Seattle Genetics Inc | Roche |
| 5852 | Marliese Alexander | Infective outcomes in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: an individual patient data meta-analysis | Peter MacCallum Cancer Centre | Roche |
| 5853 | Florian Naudet | Data-sharing and re-analysis for main studies assessed by the European Medicines Agency - a
cross-sectional study on European Public Assessment Reports
| Univ Rennes, CHU Rennes, Inserm, CIC 1414 [(Centre d’Investigation Clinique de Rennes)], F- 35000 Rennes, France | AbbVie |
| 5869 | Alexandra Freeman | Meta-analysis of the adverse effects of trastuzumab in women with breast cancer | University of Cambridge | Roche |
| 5871 | Nobuhisa Kanahara | Determination of dopamine supersensitivity psychosis in randomized controlled studies of long-acting injectable vs. oral agents of the same atypical antipsychotic in schizophrenia subjects | Chiba University Center for Forensic Mental Health | Lilly |
| 5872 | Yaw Nyame | Representation of Low-Grade Prostate Cancer in Metastatic Prostate Cancer Trials | University of Washington Medical Center | Pfizer Inc. |
| 5880 | Benjamin Schneider | Optimal Scheduling of First-Line Therapeutics in Non-Small Cell Lung Cancer | Iowa State University | Lilly, Roche |
| 5894 | Takashi Sozu | Matrix Decomposition in Meta-Analysis for Extraction of Adverse Event Pattern and Patient-Level Safety Profile | Tokyo University of Science | Lilly |
| 5897 | John Peipert | FACIT Fatigue in Rheumatoid Arthritis in Pfizer Trials | Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine | Pfizer Inc. |
| 5901 | Junhao Hu | sGC change in COVID-19 patients lung | Interdiscipline Research Center on Biology and Chemistry, Chinese Academy of Science | Hannover Medical School |
| 5902 | Thrasyvoulos Tzellos | Development and validation of a IHS4 dichotomous outcome for assessing anti-inflammatory treatment efficacy for the treatment of hidradenitis suppurativa | Department of Dermatology, Nordland University Hospital, Bodø, Norway | AbbVie |
| 5904 | Saskia Middeldorp | Hokusai post VTE study: long-term outcome after heparin plus edoxaban versus heparin plus vitamin K antagonists for acute deep vein thrombosis and pulmonary embolism | Amsterdam UMC, location AMC, University of Amsterdam | Daiichi Sankyo, Inc. |
| 5921 | Paul Schulz | Identification of biomarkers associated with Alzheimer’s disease progression that correlate with responses to medications. | University of Texas Health Science Center Houston | Lilly |
| 5924 | Iris Sommer | Meta-analysis of efficacy of cholinesterase inhibitors on individual neuropsychiatric symptoms in Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies | UMCG | GlaxoSmithKline, AbbVie, Johnson & Johnson |
| 5925 | Min Hwan Kim | CDK4/6 inhibitor NLR | Division of Medical Oncology, Yonsei University College of Medicine | Pfizer Inc. |
| 5930 | Youssef Zeidan | Evaluation of Radiotherapy Boost in Women with HER-2 positive Breast Cancer | American University of Beirut Medical Center | Roche |
| 5931 | Youssef Zeidan | Evaluation of Radiation Therapy in Triple Negative Breast Cancer | American University of Beirut Medical Center | Roche |
| 5933 | Ahmad Abuhelwa | Predictors of exposure, therapeutic and adverse effects of certolizumab pegol, baricitinib and tocilizumab used in the treatment of rheumatoid arthritis. | University of Sharjah | UCB, Lilly, Roche |
| 5940 | Aziz Mezlini | A novel statistical approach to detect the efficacy of drugs that have heterogeneous treatment effects | Massachusetts General hospital/ Harvard Medical school | GlaxoSmithKline, Takeda, AbbVie, Lundbeck, Boehringer Ingelheim, Roche, Johnson & Johnson, UCB |
| 5944 | Pietro Spitali | Prediction of disease progression in Duchenne muscular dystrophy | Leiden University Medical Center | Cure Duchenne |
| 5945 | Neeraj Narula | Predictors of Mucosal Healing in Ulcerative Colitis: A Post-hoc Analysis of VARSITY | McMaster University | Takeda |
| 5948 | Georgia Salanti | HTx project | Institute of Social and Preventive Medicine. University of Bern, Switzerland | Biogen |
| 5950 | Shirley Wang | Understanding effectiveness of new drugs in older adults shortly after market entry | Brigham and Women's Hospital | Boehringer Ingelheim |
| 5951 | Mathilde Nijkeuter | INDIVIDUALIZED PREDICTION OF RECURRENCE RISK REDUCTION AND RISK OF BLEEDING WITH EXTENDED ANTICOAGULATION IN PATIENTS WITH VENOUS THROMBOEMBOLISM v2.0 | UMC Utrecht | Daiichi Sankyo, Inc., Boehringer Ingelheim |
| 5959 | John Dennis | Stratification of SGLT2 inhibitor glucose lowering therapy in Type 2 diabetes | University of Exeter Medical School | Boehringer Ingelheim, Takeda |
| 5960 | Matt Linnik | Covid-19 Pulmonary Gene Expression Analysis | Eli Llilly | Hannover Medical School |
| 5963 | Elyse Katz | A secondary Data-Analysis to determine treatment effectiveness in Post-Traumatic Stress Disorder | Department of Defense, USSAMMDA | Lilly |
| 5968 | Mehul Patel | Methods for Staging disease activity In ulcerative colitis; A comparison of endoscopy and Histology (MESIAH) | King's College Hospital NHS Foundation Trust | Takeda, Johnson & Johnson |
| 5974 | Robert Schoevers | Prescriber effects on outcome of psychopharmacological treatment of Major Depressive Disorder (MDD) | University Medical Center Groningen, department of psychiatry, University of Groningen (RUG) | Lilly |
| 5981 | Mark Peterson | Identifying and quantifying predictors of disease progression in common measures of physical function among boys with Duchenne Muscular Dystrophy (DMD) | Vertex Pharmaceuticals, Inc. | Cure Duchenne, Lilly |
| 5982 | Matthew Baker | Investigating the effects of rituximab on specific cell subsets and cytokine levels in systemic lupus erythematosus patients and constructing a prediction model of treatment response | Stanford University | Roche |
| 5984 | David Baker | Exploring possibilities to improve the risk: benefit balance through analysis of the ocrelizumab phase II extension study | Queen Mary University of London | Roche |
| 5985 | Jose Antonio Pereira da Silva | Long-term predictive value of patient global assessment regarding radiographic damage and physical function in patients with Rheumatoid Arthritis: individual patient data meta-analysis | Universidade de Coimbra, Portugal | AbbVie, UCB, Pfizer Inc., Roche |
| 5988 | Elad Sharon | The Role of Targeted Agents and Their Effects on Lymphocytes and Patient Outcomes | National Cancer Institute | Roche |
| 5989 | Alexandre Betourne | Sharing of Progressive Supranuclear Palsy (PSP) data with the Rare Disease Cures Accelerator- Data and Analytics Platform for Analysis of Outcome Measures and Other Purposes | Critical Path Institute | AbbVie |
| 5990 | Yan Luo | Predicting the Treatment Response of Biologics for Individual Patients with Rheumatoid Arthritis: An Individual Participant Data Meta-Analysis | Kyoto University | AbbVie, Roche |
| 6003 | Andrea Quattrone | Evaluation of disease progression rate in progressive supranuclear palsy using MRI biomarkers: new implications for clinical trials | Magna Graecia University of Catanzaro, Italy | AbbVie |
| 6004 | Lily Lim | Identifying Trajectories of Disease Activity States in Juvenile Idiopathic Arthritis (JIA) Early After Treatment: Shortening Time to Decision to Change Treatment | Rady Faculty of Health Sciences, University of Manitoba | Roche |
| 6006 | Nicholas White | A Multiple-Dose Study to Assess the Effects of Azithromycin plus Chloroquine on Electrocardiograms in Healthy Subjects - COVID-19 | Mahidol Oxford Research Unit, Faculty of Tropical Medicine, Mahidol University | Pfizer Inc. |
| 6007 | Judith Goldstein | National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) Calibrations for Low Vision Patients with age-related macular degeneration (AMD) | Johns Hopkins School of Medicine | Roche |
| 6008 | David Hsieh | Patterns of outcomes and the relevance surrogate endpoints in patients treated with immune checkpoint inhibitors | University of Texas Southwestern Medical Center | Roche |
| 6041 | Neeraj Narula | Histologic Predictors of Endoscopic Healing in Crohn's Disease | Hamilton Health Sciences | AbbVie |
| 6050 | Paul Cinciripini | Safety and efficacy of smoking cessation treatments in smokers with and without depression | UT MD Anderson Cancer Center | Pfizer Inc. |
| 6055 | Florian Naudet | Inferential reproducibility of therapeutic research: a registered report for a cross-sectional study of RCTs available on major data-sharing platforms | CHU Rennes | BioLINCC (a data-sharing platform funded by the National Institutes of Health), Boehringer Ingelheim, ImmPort (a data-sharing platform funded by the National Institutes of Health), Pfizer Inc., Takeda, AbbVie, Roche, UCB, Lilly, Project Data Sphere |
| 6062 | Alexander Meisel | Neutrophils, NLR and Neutropenia as Predictors of Treatment Efficacy of Atezolizumab Monotherapy and Atezolizumab-Chemotherapy-Combinations | University Hospital of Zurich | Roche |
| 6063 | Wiesje van der Flier | Optimizing Trial design to Achieve Personalized prevention of Alzheimer’s disease | Amsterdam UMC, VUmc | GlaxoSmithKline, Lilly, Boehringer Ingelheim, Johnson & Johnson |
| 6064 | Neeraj Narula | Comparative Effectiveness of Vedolizumab vs. Infliximab in Ulcerative Colitis | Hamilton Health Sciences | Takeda, Johnson & Johnson |
| 6066 | Vivek Sharma | EVALUATING THE ASSOCIATION BETWEEN PROTEINURIA AND THROMBOSIS AND ITS PREDICTORS IN PATIENTS TREATED WITH BEVACIZUMAB | University of Louisville | Roche, Lilly, Boehringer Ingelheim |
| 6104 | Pratik Sinha | Heterogeneous treatment effects in molecular phenotypes of sepsis | Department of Anesthesia, Washington University | Lilly |
| 6464 | Michael Wiese | Individualisation of gout flare prophylaxis when initiating urate-lowering therapy | University of South Australia | Takeda |
| 6471 | Vincent Lanting | Risk of recurrent venous thromboembolism and bleeding in cancer patients: an individual patient data meta-analysis | University of Amsterdam Academic Medical Center | Pfizer Inc. |
| 6472 | Soong June Bae | Impact of neutrophil to lymphocyte ratio and BMI on prognosis in patients with HER2-positive breast cancer regarding the HER2-targeted therapy | Gangnam Severance Hospital, Yonsei University College of Medicine | Roche |
| 6475 | Tobias Polak | Combining data from expanded access programs and conventional clinical trials: a statistical application to vemurafenib | Erasmus Medical Center, Erasmus University Rotterdam | Roche |
| 6477 | Tobias Polak | Tositumomab : statistical modeling of expanded access programs and conventional trials | Erasmus Medical Center, department of Biostatistics | GlaxoSmithKline |
| 6482 | Andreas Monsch | Analyses of available cognitive data from 200 healthy, German-speaking individuals to be used to examine potential patients | University Department of Geriatric Medicine FELIX PLATTER, University of Basel, Switzerland | Takeda |
| 6483 | Bharati Kumar | Evaluation of available statistical methods performance under non-proportional hazards | University of Bath | Lilly, AstraZeneca |
| 6484 | Ari Rosenberg | Developing predictive and prognostic Artificial Intelligent (AI) digital biomarkers for soft tissue sarcoma | University of Chicago | Lilly |
| 6489 | Line Uhrenholt | Tapering strategies of biological and targeted synthetic disease-modifying antirheumatic drugs for patients with inflammatory arthri-tis: a systematic review of randomised controlled trials
| Aalborg University Hospital | AbbVie |
| 6494 | Maria Alice Franzoi | Implications of body mass index on the biological and clinical effects of endocrine therapy and abemaciclib in the neoadjuvant setting | Institut Jules Bordet | Lilly |
| 6495 | Günter Höglinger | Application of improved statistical methodologies for clinical trials in Progressive Supranuclear Palsy | Department of Neurology, Hanover Medical School, Hanover, Germany | AbbVie |
| 6496 | Neeraj Narula | Endoscopic Disease Severity and Patient Reported Outcomes in Crohn’s Disease | Hamilton Health Sciences | Johnson & Johnson, AbbVie |
| 6498 | Timo Uphaus | Identifying patients with unknown stroke etiology who may benefit from a blood thining medication with Dabigatran by a clinically based scoring system | University Medical Center Mainz | Boehringer Ingelheim |
| 6499 | Ashley Hopkins | Predictors of therapeutic and adverse effects of medicines used in the treatment of breast cancer_012021 | Flinders University | Lilly, Roche, Boehringer Ingelheim, Pfizer Inc., AstraZeneca |
| 6515 | Leire Leache | Cochrane systematic review-Pharmacotherapy for hypertension-induced left ventricular hypertrophy | Navarre Health Service (Spain) | Boehringer Ingelheim |
| 6521 | Ethan Alt | Bayesian probability of success for multivariate generalized linear models | University of North Carolina at Chapel Hill | Biogen |
| 6532 | Odelia Cooper | A study of how growth hormone treatment affects health outcomes inpatients with noncancerous craniopharyngioma tumors | Cedars-Sinai Medical Center | Lilly |
| 6534 | Diego Tosi | Analysis of breast cancer molecular adaptation to drugs in order to predict relapse after curative treatment | Institut du Cancer de Montpellier (ICM), Montpellier, France | Lilly |
| 6541 | Dipak Kotecha | Big data and meta-analytic approaches for better phenotyping in atrial fibrillation and heart failure | University of Birmingham, Institute of cardiovascular sciences | Boehringer Ingelheim |
| 6543 | Andreas Meid | Reproducible Machine Learning (ML) for Tumor Growth Inhibition (TGI) - can ML methods support the validity of conventional TGI metrics? | Heidelberg University Hospital | Roche |
| 6544 | Angela Wu | Investigating the association between smoking cessation and mental health in people with and without psychiatric disorders | Oxford University | Pfizer Inc. |
| 6550 | James Brorson | Examination of survivor functions from SOCRATES and THALES trials for kinetics of stroke recurrence | The University of Chicago | AstraZeneca |
| 6551 | Siddharth Singh | Predicting the short- and long-term risk of serious infections in patients with Crohn’s disease: Analysis of the PYRAMID Registry | University of California San Diego | AbbVie |
| 6593 | Matthieu Roustit | Exploration of regional heterogeneity in trials assessing the efficacy of recent non-insulin glucose lowering drugs on cardiovascular outcomes | Centre d'Investigation Clinique, Inserm CIC1406 CHU Grenoble AlpesLaboratoire HP2, Inserm UMR 1042 | AstraZeneca |
| 6594 | Manju Subramanian | The Impact of Race on Short Term Treatment Response to Intravitreal anti-Vascular Endothelial Growth Factor in Diabetic Macular Edema: A Pooled Analysis | Boston University Medical Center | Roche |
| 6601 | Dan Turner | Adaptation and validation of the Mucosal Inflammation Non-invasive (MINI) Index for Crohn's disease in adults using the SERENE clinical trial data | Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Israel | AbbVie |
| 6632 | Luca Valerio | Healthcare resource utilization and economic burden related to pulmonary embolism. An analysis of the PREFER in VTE study. | Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg-University Mainz | Daiichi Sankyo, Inc. |
| 6633 | Luca Valerio | Performance status and long-term clinical outcomes in pulmonary embolism patients with cancer. An analysis of Hokusai VTE Cancer study | Center of Thrombosis and Hemostasis, University Medical Center Mainz, Mainz, Germany; Department of Cardiology | Daiichi Sankyo, Inc. |
| 6641 | Anna Feeney | Antidepressants in children and adolescents with Major Depressive Disorder and the influence of placebo response: a meta-analysis | Massachusetts General Hospital/ Harvard Medical School | Pfizer Inc. |
| 6642 | Neeraj Narula | Modified Multiplier SES-CD (MM-SES-CD) on Predicting Endoscopic Remission in Crohn’s Disease | Hamilton Health Sciences | AbbVie, Takeda, Johnson & Johnson |
| 6686 | Neeraj Narula | Extended Validation of an Ulcerative Colitis Vedolizumab Decision Support Tool | Hamilton Health Sciences | Takeda |
| 6710 | Gus Slotman | Identifying Patients in the PROWESS SHOCK Clinical Trial Among Whom Drotrecogin Alfa (DrottAA) Reduced Mortality | Inspira Health Network, Vineland, NJ | Lilly |
| 6712 | Yeon-Mok Oh | Development and validation of a prediction model for the indication of inhaled corticosteroid (ICS) in patients with chronic obstructive pulmonary disease (COPD) | Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea | GlaxoSmithKline |
| 6716 | Nigam Shah | Applying machine learning tools to personalize dabigatran treatment decisions | Stanford Universty | Boehringer Ingelheim |
| 6732 | Yung-Chuan Huang | Decision Tree Model for Dose Selection in Non-valvular Atrial Fibrillation Patients | Fu Jen Catholic University | Boehringer Ingelheim |
| 6734 | Andreas Suhrbier | The K18 mouse model recapitulates the transcriptomic response to acute COVID-19 Acute Respiratory Distress syndrome (ARDS) in humans | QIMR Berghofer Medical Research institute | Hannover Medical School |
| 6739 | Rifaquat Rahman | Evaluation of Differences in Trial and Non-Trial Patients and Leveraging of External Data for More Efficient Clinical Trial Designs in Newly Diagnosed Glioblastoma | Dana-Farber/Brigham and Women's Cancer Center (Dana-Farber Cancer Institute) | Roche, Project Data Sphere |
| 6740 | Georgios Paliouras | in-silico DMD: Developing computational predictive models for the progression of Duchenne Muscular Dystrophy | National Center for Scientific Research "Demokritos", Greece | Cure Duchenne |
| 6758 | Qian Chen | Retrospective analysis of the effect of first-line bevacizumab treatment on survival and prognosis of patients with advanced non-small cell lung cancer treated with second-line immunotherapy | Hubei Cancer Hospital | Roche |
| 6759 | Zhi Xiao | Roles of neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) in prognosis and in differentiation of potential beneficiaries in HER2-positive breast cancer with trastuzumab therapy | Xiangya Hospital, Central-South University | Roche |
| 6762 | Jian-Guo Zhou | Longitudinal peripheral blood markers as dynamic predictors to identify efficacy and safety of patients treated with immune checkpoint inhibitors (ICIs) | Second Affiliated Hospital of Zunyi Medical University | Project Data Sphere, Roche, Bristol Myers Squibb |
| 6764 | Jonathan Bartlett | Hypothetical estimands in clinical trials: an application of causal inference and missing data methods | London School of Hygiene and Tropical Medicine | AstraZeneca |
| 6765 | Dan Hanley | Pandemic response COVID-19 Research Collaboration Platform | Johns Hopkins University | NYU Grossman School of Medicine, Intermountain Healthcare, Washington University, St. Louis, Bassett Medical Center, The Queen's Medical Center, Duke University School of Medicine/Duke University Hospital, University Medical Center, New Orleans |
| 6836 | Alana Rojewski | Smoking Cessation Pharmacotherapy Efficacy in Comorbid Medical Populations: Secondary Analysis of the EAGLES Randomized Clinical Trial | Medical University of South Carolina | Pfizer Inc. |
| 6860 | Nicholas Lange | Belatacept in obese kidney transplant recipients | Columbia University Irving Medical Center | Bristol Myers Squibb |
| 6866 | Andy Lim | Meta-analysis of early stroke recurrence rate in minor stroke | Monash Health | AstraZeneca |
| 6869 | Zhen Lin | Evaluating Clinical trial data conventions for the Observational Medical Outcomes Partnership Common Data Model | Co-founder and CEO, Robot Bacon Corporation | Roche, GlaxoSmithKline, Takeda, AstraZeneca, Ferox Therapeutics |
| 6881 | Stefan Leucht | Individual-patient-data (IPD) meta-analysis of the efficacy of clozapine versus second-generation antipsychotic drugs in patients with treatment-resistant schizophrenia | Section for Evidence-based Psychiatry, Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany | Lilly |
| 7062 | Julien Edeline | PATIENT REPORTED OUTCOME (PRO) AS A PROGNOSTIC MARKER IN PATIENTS TREATED WITH TARGETED THERAPIES FOR ADVANCED HEPATOCELLULAR CARCINOMA (PRO²-HCC) | Centre Eugene Marquis | Bristol Myers Squibb |
| 7070 | Georgios Tsakonas | Anaplastic Lymphoma Kinase- Brain Prognostic Index (ALK-BPI) a novel prognostic score for brain metastasized ALK+ Non Small Cell Lung Cancer (NSCLC) | Karolinska University Hospital/Karolinska Institutet | Roche |
| 7072 | James Signorovitch | Development of natural history controls to contextualize clinical trial outcomes of boys with Duchenne muscular dystrophy treated with DS-5141b | Analysis Group, Inc. | Cure Duchenne |
| 7074 | Gregory YH Lip | Impact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomes | University of Liverpool, Liverpool, Merseyside, United Kingdom | Boehringer Ingelheim |
| 7076 | Elias Eriksson | Post hoc patient-level analysis of the impact of amitriptyline, selective serotonin reuptake inhibitors, and placebo of individual items of the Hamilton Depression Rating Scale | Dept. of Pharmacology, Inst. for Neuroscience and physiology, Sahlgrenska Academy, University of Gothenburg, Sweden | GlaxoSmithKline |
| 7077 | Neeraj Narula | Dominant Patient Reported Outcomes on Predicting Mucosal Healing in Crohn’s Disease | Hamilton Health Sciences | Johnson & Johnson, AbbVie |
| 7078 | Alberto Martini | Role of Body Mass Index and concomitant medication use in metastatic urothelial carcinoma | University of Cincinnati | Roche |
| 7101 | Jason Luke | Analysis of gene expression profiles in melanoma tumors exhibiting differential lactate dehydrogenase biomarker levels and correlation with immunotherapy response | University of Pittsburgh; UPMC Hillman Cancer Center | Bristol Myers Squibb |
| 7104 | Jakob Näslund | Item-level effects of adjuvant olanzapine and/or olanzapine monotherapy in treatment-resistant depression | University of Gothenburg | Lilly |
| 7126 | Alessio Cortellini | The predictive role of inflammation indices in patients treated with immunotherapy or chemotherapy for advanced non-small cell lung cancer | Imperial College London | Roche |
| 7127 | Alexa Kimball | Effects of adalimumab on inflammation-associated hematologic abnormalities in patients with Hidradenitis Suppurativa | Beth Israel Deaconess Medical Center | AbbVie |
| 7136 | Shou-Ching TANG | Validation of trastuzumab-emtansine (T-DM1) Toxicity Score to predict response to T-DM1 treatment in metastatic breast cancer | UMMC Cancer Center and Research Inst. | Roche |
| 7140 | Michael J. Sorich | Early markers of clinical outcome to ipilimumab therapy for advanced melanoma | Flinders University of South Australia | Bristol Myers Squibb |
| 7142 | Sara Tedeschi | Causal inference cohort re-analysis of the 'CARES' trial to better understand the roles of colchicine, allopurinol, and febuxostat on cardiovascular events among patients with gout | Brigham and Women's Hospital | Takeda |
| 7143 | Chaim Singal | The effects of systemic anti-infective concomitant medications on progression of neurological diseases | experiMind | GlaxoSmithKline, Lilly, Boehringer Ingelheim, UCB |
| 7144 | Timothy Perk | External validation of the AIQ predictive score of clinical benefit using Sodium Fluoride (NaF) position emission tomography/computed tomography (PET/CT) images in metastatic prostate cancer (mPC). | AIQ Solutions | Pfizer Inc. |
| 7145 | Joan Busner | Psychometric evaluation of PANSS in adolescent schizophrenia trials | Signant Health | Otsuka Pharmaceuticals |
| 7147 | Carmela Tartaglia | Exploring the heterogeneity of cognitive profile in patients with Progressive Supranuclear Palsy (PSP) enrolled in the ABBV-8E12 trial and the relationship to brain volumes | University of Toronto | AbbVie |
| 7156 | Angelina Tjokrowidjaja | Concordance between disease progression by Cancer Antigen 125 and computerized tomography (CT) progression in patients with relapsed advanced ovarian cancer treated with poly(adenosine diphosphate [ADP]–ribose) polymerase inhibitor: a pooled analysis | University of Sydney NHMRC Clinical Trials Centre | AstraZeneca |
| 7158 | Neeraj Narula | Patient Reported Symptoms as Predictors of Endoscopic Improvement in Ulcerative Colitis | Hamilton Health Sciences | Takeda |
| 7159 | James Signorovitch | Associations between steroid treatment, functional outcomes and disease milestones among subgroups of patients with Duchenne muscular dystrophy (DMD) | Analysis Group | Cure Duchenne |
| 7161 | Wesley Kerr | Real-time monitoring of individual response to antiseizure medication treatment during clinical trials | UCLA | UCB, GlaxoSmithKline, Johnson & Johnson |
| 7162 | Andrew Bottomley | Cancer Clinical Trials Pooling of Quality Life Data (CATAPULT) initiative | European Organisation for Research and Treatment of Cancer (EORTC) | Bristol Myers Squibb |
| 7163 | Laura Mezquita | Prospective validation of the Lung Immune Prognostic Index in patients with non-small cell and small cell lung cancers. | Hospital Clinic and the Translational Genomics Group at IDIBAPS | Roche, Project Data Sphere |
| 7164 | Jörg Ellinger | Evaluation of CRP (c-reactive protein) flare phenomena as an early predictor of response to the Atezolizumab + Bevacizumab therapy in renal cell carcinoma | University Hospital Bonn, Germany | Roche |
| 7224 | Keiichi Fujiwara | Early prediction of survival outcome of large-scale randomized clinical trials using artificial intelligence technology | Gynecologic Oncology Trial and Investigation Consortium (GOTIC) | Roche, Boehringer Ingelheim, Lilly |
| 7225 | Neeraj Narula | Early vs. Delayed Response to Vedolizumab in Ulcerative Colitis | Hamilton Health Sciences | Takeda |
| 7227 | Catrin Tudur-Smith | Add-on treatment for refractory focal-onset epilepsy: Individual Participant Data Network Meta-analysis | University of Liverpool | UCB, GlaxoSmithKline, Johnson & Johnson |
| 7232 | Neil Oxtoby | Identification of heterogeneity in Alzheimer’s disease clinical trials using computational modelling | University College London | Takeda |
| 7241 | Frederick Reimherr | Retrospective Analysis of Emotional Symptoms in Adults with ADHD and Improvement Produced by Brexpiprazole | Psychiatric and Behavioral Solutions, LLC | Otsuka Pharmaceuticals |
| 7243 | Emanual Maverakis | Developing Models from Existing Atopic Dermatitis Outcome Data | University of California Davis | GlaxoSmithKline |
| 7245 | Manabu Takaki | Clinical moderators of response to nalmefene in alcohol dependence: Results from a randomized controlled trial in Japan. | Okayama University | Otsuka Pharmaceuticals |
| 7274 | Jun Chen | Efficacy comparision of biologics (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) in treatment of severe eosinophilic asthma -- a network meta-analysis | West China Hospital, Sichuan University | GlaxoSmithKline |
| 7277 | Eric Harvey | Integrating clinical data from 2 trials into the International COVID-19 Data Alliance (ICODA) Workbench | MMS Holdings | Roche |
| 7283 | Franziska Michor | Large-scale public data reuse to model immunotherapy response and resistance | Dana-Farber Cancer Institute/Harvard University | Bristol Myers Squibb |
| 7288 | Vipual Jairath | Placebo Rates in Inflammatory Bowel Disease: An Individual Patient Data Meta-analysis of Randomized Controlled Trials | Alimentiv Inc | AbbVie, Takeda, Johnson & Johnson |
| 7289 | Gianluca Rigatelli | Outcomes of Left Main Purcutaneous Coronary Intervention (PCI) across age classes | Ausl5, Rovigo General Hospital | Duke University School of Medicine/Duke University Hospital |
| 7312 | Marianna Kruithof-de Julio | Machine learning for personalized drug response prediction for bladder and prostate cancer patients | DEPARTMENT FOR BIOMEDICAL RESEARCH (DBMR), UNIVERSITY OF BERN, AND UNIVERSITY HOSPITAL FOR UROLOGY, INSELSPITAL BERN | Tempus AI, Inc. |
| 7317 | Emanual Maverakis | Developing Efficacy Assessment Tools from Existing Psoriasis Clinical Trial Outcome Data | University of California Davis | Lilly |
| 7321 | Neeraj Narula | A Comparison of the Rapidity of Clinical Response between Infliximab and Tofacitinib for Ulcerative Colitis | Hamilton Health Sciences | Pfizer Inc., Johnson & Johnson |
| 7322 | Zhengfei ZHU | Clinical value and optimal candidate of cranial radiotherapy in atezolizumab-treated advanced non-small cell lung cancer with baseline brain metastasis | Fudan University Shanghai Cancer Center | Roche |
| 7323 | Toshifumi Kishimoto | Development of the optimal treatment of Nalmefene in patients with alcohol dependence | Nara Medical University | Otsuka Pharmaceuticals |
| 7325 | Andreas Artemiou | Predicting outcomes (death, survival) of COVID-19 patients on Standard of Care (SoC) . | Cardiff University | Roche, NYU Grossman School of Medicine, University Medical Center, New Orleans |
| 7379 | Michele Romoli | Antithrombotics in patent formane ovale (PFO)-related stroke: a meta-analysis stratified for the risk of paradoxical embolism score (RoPE) | Bufalini Hospital | Boehringer Ingelheim |
| 7381 | Tomoya Hirota | Early Prediction of Treatment Response to Antipsychotics for Irritability and Aggression in Autism Spectrum Disorder | University of California San Francisco | Otsuka Pharmaceuticals, Johnson & Johnson |
| 7384 | Ulrich Mansmann | Application of Estimands and Causal Reasoning in the Reanalysis of Endpoint Measures in Advanced/Metastatic Non-Small Cell Lung Cancer Clinical Trials | Department for Medical Information Processing, Biometry, and Epidemiology; Ludwig-Maximilian’s University München; Marchioninistrasse 15 D-81377 München | Takeda, Roche, AstraZeneca |
| 7387 | Neeraj Narula | Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn’s Disease | Hamilton Health Sciences | Takeda, AbbVie, Johnson & Johnson |
| 7388 | Byeongzu Ghang | Reanalysis of CARES study to investigate the changes of estimated glomerular filtration rate after long-term febuxostat or allopurinol treatment in gout patients | Division of Rheumatology, Jeju National University School of Medicine, Jeju National University Hospital | Takeda |
| 7394 | Ashley Hopkins | Predictors of exposure, therapeutic and adverse effects of atezolizumab used in the treatment of advanced cancers_092021 | Flinders University | Roche |
| 7395 | Xiaoling Shang | Survival analysis of advanced lung adenocarcinoma harboring epidermal growth factor receptor gene mutation receiving the combination treatment of atezolizumab, bevacizumab, carboplatin and paclitaxel. | Shandong University | Roche |
| 7396 | Mary Ann Lukas | Modeling and Simulation of ambrisentan pharmacokinetics in young children | GlaxoSmithKline | Duke University School of Medicine/Duke University Hospital |
| 7399 | Yoichi Naito | Combined analysis of randomized phase III study ANNOUNCE and randomized phase II study exploring olaratumab. | National Cancer Center East | Lilly |
| 7400 | Aryelly Rodriguez | What are the re-identification risk scores of publicly available anonymised clinical trial datasets? | The University of Edinburgh | GlaxoSmithKline, UCB |
| 7401 | Scott Garrison | Randomized Controlled Trial Data Availability and Re-Analysis Project | Faculty of Medicine and Dentistry, University of Alberta | Roche, University of Washington, Pfizer Inc. |
| 7404 | Reena Khanna | A Study to Assess the Correlation Between Harvey Bradshaw Index and Patient Reported Outcome 2 in Crohn's Disease Patients Enrolled in Large Scale Randomized Controlled Trials | Lawson Health Research Institute | Takeda |
| 7414 | Nobuyuki Horita | Progression-Free Survival, Response Rate, and Disease Control Rate as Predictors of Overall Survival in Trials Evaluating Atezolizumab Regimens for Advanced, Locally Advanced, and Recurrent Non-Small Cell Lung Carcinoma | Chemotherapy Center, Yokohama City University Hospital | Roche |
| 7427 | Joachim Tan | Dose reduction and discontinuation of disease modifying anti-rheumatic drugs (DMARDs) for juvenile idiopathic arthritis | Monash University | AbbVie, Johnson & Johnson, Roche |
| 7435 | Noah Goldfarb | Decision tool for the use of adalimumab for hidradenitis suppurativa | University of Minnesota | AbbVie |
| 7445 | Catherine Thieblemont | Evaluation of surrogate markers in marginal zone lymphoma | Inserm | Roche |
| 7462 | Junjie Zhuo | Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles with Clinical Profiles in the Progression of Alzheimer’s Disease | Hainan University | AstraZeneca |
| 7492 | Yang Zhao | An Investigation on the Role of Blood Biomarkers as Predictors for Individualized Treatment Regimen Selection in Non-Small Cell Lung Cancer. | Nanjing Medical University | Roche |
| 7493 | Nina Hilkens | Blood pressure variability and progression of white matter hyperintensities after ischemic stroke | Radboudumc Nijmegen | Boehringer Ingelheim |
| 7495 | Thomas Antalffy | Analysing Clinical Applicability of CompEx Endpoints | Smart Respiratory Products Ltd | AstraZeneca |
| 7498 | Riccardo Polosa | A Machine Learning approach to improve smoking cessation trials | Center of Excellence for the Acceleration of Harm Reduction (CoEHAR), University of Catania | Pfizer Inc. |
| 7501 | Min-Gul Kim | COVID-19 clinical trial data utilization to develop external control datasets in COVID-19 therapeutics development | Jeonbuk National University Hospital | Hospital Universitario Austral, Montreal Heart Institute, University of Minnesota, Lilly, Roche, HCor Research Institute |
| 7503 | Leslie Padrnos | systematic review and meta-analysis Heme Malignancy VTE anticoagulation | Mayo Clinic Arizona | Boehringer Ingelheim, Pfizer Inc., Daiichi Sankyo, Inc. |
| 7518 | Lucio Manenti | Role of persistent and isolated reduced serum complement 3 (C3) in lupus nephritis | UNIVERSITY HOSPITAL OF PARMA | Roche |
| 7520 | Malathi Ram | ACEi/ARB medications for hospitalized patients with COVID-19 – an individual patient data (IPD) based pooled analysis | Johns Hopkins Bloomberg School of Public Health | University of Kansas Medical Center, Sharp Healthcare, University of Minnesota, Bassett Medical Center |
| 7535 | Joshua Drago | Statin use and clinical outcomes on ado-trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer | Memorial Sloan Kettering Cancer Center | Roche |
| 7539 | Amit Etkin | Clinical and demographic predictors of antidepressant treatment in patients with major depressive disorder with agomelatine versus vortioxetine | Alto Neuroscience, Inc. | Lundbeck |
| 7541 | Amit Etkin | Role of clinical, historical and demographic factors in the response to antidepressants versus placebo | Alto Neuroscience, Inc | Lilly, Takeda |
| 7542 | Neeraj Narula | Vedolizumab vs. Adalimumab in Ulcerative Colitis: Validation of Indirect Comparisons | Hamilton Health Sciences | AbbVie, Takeda |
| 7543 | Margaret Salisbury | Disease progression modeling to detect treatment effects in pulmonary fibrosis | Vanderbilt University Medical Center | Roche, Boehringer Ingelheim |
| 7544 | Cynthia Comella | Sensory trick and benefit from botulinum toxin in cervical dystonia | Rush University Medical Center | AbbVie |
| 7549 | Vipul Jairath | Responsiveness of the UC-100 Score in Patients with Moderately to Severely Active Ulcerative Colitis | Alimentiv Inc. | AbbVie, Takeda, Johnson & Johnson |
| 7552 | Anna van Eijk | Impact of Malaria in Pregnancy on Infants Study Group | Liverpool School of Tropical Medicine | Pfizer Inc. |
| 7580 | Hiroyoshi Takeuchi | Effects of gaps in doses between oral and long-acting injectable aripiprazole on clinical outcomes in schizophrenia | Department of Neuropsychiatry, Keio University School of Medicine | Otsuka Pharmaceuticals |
| 7581 | Rustam Al-Shahi Salman | Collaboration Of Controlled Randomised trials of Oral Antithrombotic agents after intraCranial Haemorrhage (COCROACH) | University of Edinburgh | Daiichi Sankyo, Inc. |
| 7583 | Youssef Zeidan | Evaluation of Radiotherapy after Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Patients | American University of Beirut | Roche |
| 7587 | Yashmin Karten | Model-Informed Drug Development (MIDD) in Alzheimer's Disease | Critical Path Institute | Lilly |
| 7590 | Noémie Lang | FRILLY: a retrospective single center study on Fractionated Rituximab to avoid Lysis Syndrome in Aggressive B-Lymphoma | University Hospitals of Geneva (HUG) | Roche, Project Data Sphere |
| 7591 | Neeraj Narula | Predictors of Placebo Response and Remission in Ulcerative Colitis and Crohn’s Disease VERSION 2.0 | Hamilton Health Sciences | AbbVie, Takeda, Johnson & Johnson, Pfizer Inc. |
| 7592 | Alexandre Betourne | Integration of Biogen Rare Disease Data into RDCA-DAP | Critical Path Institute | Biogen |
| 7595 | Ashley Hopkins | Predicting therapeutic outcomes to immune checkpoint inhibitors used in cancer treatment_012022 | Flinders University | Roche |
| 7597 | Junko Takeshita | Evaluating Racial and Ethnic Differences in the Quality-of-Life Impact of Atopic Dermatitis | University of Pennsylvania | Regeneron, Pfizer Inc., Lilly |
| 7598 | Harry Southworth | Statistical investigation of comorbidities of back pain in the medical history data from clinical trials of healthy subjects | Data Clarity Consulting Ltd | GlaxoSmithKline, AstraZeneca |
| 7599 | Hwanhee Hong | Combining data sources to identify effect moderation for personalized mental health treatment | Duke University | Johnson & Johnson, Takeda, Lundbeck |
| 7601 | Guru Sonpavde | Mathematical prognostic model utilizing multi-platform dynamics in patients with metastatic urothelial carcinoma receiving post-platinum immune checkpoint inhibitors | AdventHealth Cancer Institute, Orlando, Florida | Roche |
| 7606 | Amber Salter | Comorbidity and Clinical Trials of Disease-Modifying Therapies in Multiple Sclerosis | UT Southwestern Medical Center | Roche |
| 7609 | Joao Pedro Ferreira | The impact of albiglutide on heart failure outcomes among patients with type 2 diabetes with and without heart failure at baseline | Porto University | GlaxoSmithKline |
| 7620 | Emilie Sbidian | Systemic pharmacological treatments for chronic plaque psoriasis: A Systematic Review and an Individual-Patient Data Network Meta-Analysis of Randomized Controlled Trials | University Paris Est Creteil (UPEC) | AbbVie, Lilly, Pfizer Inc., Johnson & Johnson, UCB |
| 7621 | Adam Boxer | Bayesian Disease Progression Modeling and Clinical Trial Design for Progressive Supranuclear Palsy - Richardson's Syndrome | UCSF | AbbVie |
| 7654 | Shirley Yu | Update of individual data meta-analysis of intra-articular corticosteroids in knee and hip osteoarthritis | Institute of Bone and Joint Research, University of Sydney Department of Rheumatology, Royal North Shore Hospital. Sydney, Australia | Sanofi |
| 7656 | Neeraj Narula | Impact of Steroid Weaning Regimens on Outcomes in Clinical Trials of Ulcerative Colitis | Hamilton Health Sciences | Johnson & Johnson, AbbVie, Takeda, Pfizer Inc. |
| 7658 | Arman Sabbaghi | Tripartite Estimands for Adherence Causal Inference in Clinical Trials, With Applications for the Development of COVID-19 Treatments | Statistics, Purdue University | Sanofi |
| 7660 | Shirley Yu | Predictors of placebo response to intra-articular therapy in osteoarthritis - an individual patient data meta-analysis | Institute of Bone and Joint Research, University of Sydney Department of Rheumatology, Royal North Shore Hospital. Sydney, Australia | Sanofi |
| 7661 | Baocheng Chang | Effects of Lixisenatide on the primary prevention of diabetic kidney disease in population with high risk | Chu Hsien-I Memorial Hospital, Tianjin Medical University | Sanofi |
| 7662 | Benoit You | Prognostic And Predictive Value Of The Modeled PSA Kinetics Parameters In Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel Or Cabazitaxel (Phase III Trial — FIRSTANA) | Université Claude Bernard Lyon | Sanofi |
| 7663 | Amit Etkin | Cognition and clinical factors as predictors of antidepressant treatment outcome in patients with major depressive disorder | Alto Neuroscience, Inc. | Takeda, Lundbeck, Lilly |
| 7667 | Ashley Hopkins | Summarising the therapeutic and adverse effects of anticancer medicines according to race and sex: pooled analysis of clinical trials of contemporary treatments for solid tumours | Flinders University | AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Inc., Lilly, Roche, Pfizer Inc., Sanofi, Takeda, Johnson & Johnson, Bayer |
| 7743 | Caroline Quach | Is there a Difference in the Immune Response, Efficacy, and Safety of Seasonal Influenza Vaccine in Males and Females? - A Meta-Analysis. | CHU Sainte-Justine | Sanofi |
| 7758 | NAHID SULTANA | Indirect comparisons of time-to-event outcomes using single-arm studies in health technology assessment (Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma) | University of Sheffield | GlaxoSmithKline |
| 7759 | Tamar Oostrom | Heterogenous Effects in Diabetes Mellitus Clinical Trials and Implications for Physician Prescriptions | The Ohio State University | Sanofi, GlaxoSmithKline |
| 7760 | John (Devin) Peipert | Study of Functional Assessment of Chronic Illness Therapy (FACIT) GP5 Item as a Measure of Treatment Tolerability in Advanced Cancer Patients across Multiple Tumour Sites and Treatment Types | Northwestern University | Roche, Lilly, Pfizer Inc. |
| 7772 | Neeraj Narula | Combined Histologic and Endoscopic Endpoints in Ulcerative Colitis | Hamilton Health Sciences | Takeda |
| 7776 | Stefan Leucht | Antipsychotic drugs vs. placebo in the treatment of antipsychotic naive and/or first episode children or adolescents with psychosis: A systematic review and meta-analysis of double-blind randomized trials | Professor Stefan Leucht MD. Department of Psychiatry and Psychotherapy, School of Medicine, Technical University of Munich, Munich, Germany | Lilly, Otsuka Pharmaceuticals |
| 7777 | PAUL AYUK | Using Dabigatran etexilate to prevent blood clots in women after childbirth | Newcastle-upon-Tyne Hospitals NHS Trust | Boehringer Ingelheim |
| 7779 | Luís Inês | Derivation and validation of the Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) severe disease activity category: post-hoc analysis of the anifrolumab clinical trials in active systemic lupus erythematosus. | 1- Faculty of Health Sciences, University of Beira Interior, Covilhã, Portugal | AstraZeneca |
| 7782 | Yang Li | A new covariate randomization method for multi-arm randomized controlled trials | Renmin University of China | GlaxoSmithKline |
| 7785 | Christian Jonasson | Using Norwegian real world data to emulate and reproduce results from oncology clinical trials | NordicRWE | Roche |
| 7794 | Joan CARLES | Co Medication (aspirin, statins and metformin) analysis in patients with metastatic Castration Resistant Prostate Cancer treated with Chemotherapy. | VALL D HEBRON INSTITUTE OF ONCOLOGY VALL D'HEBRON UNIVERSITY HOSPITAL Passeig Vall d'Hebron 119-129 08035 BARCELONA | Sanofi |
| 7797 | Jörg Ellinger | Evaluation of the performance of the modified Glasgow prognostic score in urothelial carcinoma, non-small cell lung cancer and renal cell carcinoma | Department of Urology, University Hospital Bonn, Germany | Roche, Pfizer Inc., Project Data Sphere |
| 7801 | Yoshie Omachi | Elucidation of the predictive factors for active and placebo drug response on social functioning and quality of life (QOL) in psychiatric illnesses including developmental disorders | National Center of Neurology and Psychiatry (NCNP) | Lilly, Johnson & Johnson, Shionogi |
| 7804 | Qingyun Li | An exploratory study of the fusion co-mutated immune microenvironment in Non-small cell lung cancer | Genecast Biotechnology Co., Ltd | Roche |
| 7807 | Hayato Niiyama | A Post-hoc Analysis using Secondary Data of Clinical Trial from M14-033 Study to Evaluate Average Treatment Effect and Heterogeneous Treatment Effect of Adalimumab in Maintenance Phase for Patients with Ulcerative Colitis | School of Data Science, Yokohama City University, Japan | AbbVie |
| 7809 | David James Pinato | The prognostic impact of early antibiotics exposure on Overall Survival and Progression Free Survival of patients affected by unresectable hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab or sorafenib within the IMbrave 150 trial. | Imperial College, London | Roche |
| 7810 | Diego Chowell | Machine learning model to predict cancer immunotherapy response | Icahn School of Medicine at Mount Sinai | Roche |
| 7811 | Gustavo Turecki | Using Artificial Intelligence to Personalize Treatment Selection and Trajectory Monitoring of Bipolar Disorder | Douglas Mental Health University Institute, McGill University | Lilly, AbbVie, Takeda, Otsuka Pharmaceuticals |
| 7817 | Neeraj Narula | Predictors of Histologic Response using Antibodies Against Interleukin-5 in Eosinophilic Esophagitis | Hamilton Health Sciences | GlaxoSmithKline |
| 7818 | Werner Weitschies | Development and improvement of an in vitro tool, which simulates the physiological characteristics of the ascending colon | University of Greifswald, Center ofDrug Absorption and Transport | Sanofi |
| 7819 | Jeanine Roeters van Lennep | Efficacy & Safety of Proprotein Convertase Subtilisin/Kexin type 9 Inhibitors: a Systematic Review and Meta-analysis of Real-World Data | Erasmus University Medical Center | Sanofi |
| 7822 | Linbin Lu | Trajectories of alpha-fetoprotein and liver cancer outcomes after atezolizumab treatment | the 900th Hospital of PLA | Roche |
| 7823 | Marc Carrier | Anticoagulation for the Prevention of Arterial Thrombosis in Ambulatory Patients with Cancer: A Systematic Review | University of Ottawa | GlaxoSmithKline, Sanofi |
| 7824 | Feng Sun | An individual participant data meta-analysis to evaluate PD1 vs PD-L1 Inhibitors in Asian subgroup Cancer patients | Peking University | Daiichi Sankyo, Inc., Roche |
| 7828 | Sofia Ramiro | SPondyloarthritis: EARly Definition (ASAS-SPEAR): Analysis of Symptom Duration Thresholds Using Pooled Data from Randomized Controlled Trials | Leiden University Medical Center | Lilly, Pfizer Inc., UCB, AbbVie, Johnson & Johnson |
| 7830 | Yi-Wen Tsai | Cost effectiveness analysis of atezolizumab plus chemotherapy for untreated extensive stage small cell lung cancer in Asia | Institute of Health & Welfare Policy, National Yang Ming Chiao Tung University, Taiwan | Roche |
| 7835 | Hiroyuki Kusuhara | Assessment of the drug-drug interactions risks of drugs based on the clinical data of the plasma biomarkers | The University of Tokyo | AbbVie |
| 7840 | Marco Tagliamento | Clinical Effect of Chemotherapy-Immunotherapy Combination in the First-Line Treatment of Older Patients with Non-Small Cell Lung Cancer | IRCCS Ospedale Policlinico San Martino | Roche |
| 7842 | Marco Tagliamento | Pooled Efficacy and Safety Analysis of the Phase III Studies of Alectinib vs. Crizotinib in Untreated ALK-Positive Non-Small Cell Lung Cancer | IRCCS Ospedale Policlinico San Martino | Roche |
| 7844 | Linong Ji | Risk stratification and responder identification using a baseline model and a dynamic risk prediction model for GLP-1RA and SGLT2i in T2DM: a machine learning facilitated posthoc analysis of CVOTs | Peking University People's Hospital | GlaxoSmithKline, BioLINCC (a data-sharing platform funded by the National Institutes of Health), Johnson & Johnson |
| 7845 | Craig Nelson | Change in cognition during antidepressant treatment of late life depression | University of California San Francisco | Lilly, Lundbeck |
| 7846 | Samuele Cortese | PATIENCE Individual Patient DATa Network Meta-AnalysIs of the Efficacy aNd aCceptability of Attention-Deficit/Hyperactivity Disorder (ADHD) mEdication | University of Southampton, UK | AbbVie, Johnson & Johnson, Lilly, Takeda, Novartis |
| 7848 | Jennifer Lund | Improving Colon Cancer Therapy Decisions by Extending Trial Representation | Department of Epidemiology, University of North Carolina at Chapel Hill | Sanofi |
| 7849 | Igor Stojkov | Determinants of study design for vaccines against opportunistic bacterial infections: a proof-of-concept for data-driven, individual patient data (IPD) analyses. | Paul-Ehrlich-Institut | Sanofi |
| 7850 | Vipul Jairath | Impact of concomitant baseline medication, advanced age and racial differences on efficacy of biologics and small molecules for Inflammatory Bowel Disease | Departments of Medicine (Division of Gastroenterology) and cross-appointment to Epidemiology and Biostatistics at The University of Western Ontario | Johnson & Johnson, Takeda, UCB, Pfizer Inc., AbbVie |
| 7854 | Vipul Jairath | Efficacy of medical therapies for ulcerative colitis according to disease distribution: An individual patient data meta-analysis of randomized controlled trials | Departments of Medicine (Division of Gastroenterology) and cross-appointment to Epidemiology and Biostatistics at The University of Western Ontario | Pfizer Inc., Johnson & Johnson, AbbVie, Takeda |
| 7856 | Evandro de Azambuja | Metastatic HER2-positive breast cancer treated with docetaxel, trastuzumab, and pertuzumab: the impact of early response on patient survival | Institut Jules Bordet, Brussels, Belgium | Roche |
| 7857 | Rentao Yu | Cutaneous immune-related adverse events of immunotherapy medications in the treatment of cancers and association with survival. | the First Affiliated Hospital of Chongqing Medical University | Roche, Daiichi Sankyo, Inc. |
| 7858 | Jie Zha | Retrospective cohort study with internal and external validation of a predictive tool for POD24 risk assessment in follicular lymphoma patients | Department of Hematology, The First Affiliated and Institute of Hematology, School of Medicine, Xiamen University | Roche |
| 7860 | Kemi Williams | UNITY Global Study Nigeria Datasets | 54gene | Certara |
| 7868 | Anne-Marie Dingemans | Predictive clinical characteristics for weight gain in patients treated with alectinib | Erasmus MC University Medical Center | Roche |
| 7872 | Dorra Bouazzi | Hidradenitis Suppurativa – a collaborative study of subtypes | Department of Dermatology, Zealand University Hospital | AbbVie |
| 7873 | Xue Yang | Crizotinib followed by alectinib vs alectinib alone: analysis of treatment-naïve patients with non-small cell lung cancer (NSCLC) harboring anaplastic lymphoma kinase (ALK) -rearrangement | Beijing Cancer Hospital | Roche |
| 7874 | Chiara Alessandra Cella | Addressing the synergistic effect of metformin in patients with Pancreatic neuroendocrine tumors treated with sunitinib: a post-hoc analysis from the main pivotal trials. | Istituto Europeo di Oncologia | Pfizer Inc. |
| 7875 | Marco Valgimigli | P2Y12 inhibitor or Aspirin moNoTHERapy as secondary prevention in patients with coronary artery disease: in individual patient data meta-analysis (PANTHER collaborative initiative) | Cardiocentro Ticino, Lugano and Universita della Svizzera ltaliana (USI) | Sanofi |
| 7882 | José González-Gomariz | Study of the expression of several cytokines related with the survival in cancer melanoma patients | FIMA | Bristol Myers Squibb |
| 8052 | Wataru Fukuokaya | Association of serum magnesium levels with the effectiveness of atezolizumab in advanced urothelial carcinoma | The Jikei University School of Medicine | Roche |
| 8053 | Alexander G Mathioudakis | ICS-RECODE: Predictors of treatment REsponse to inhaled corticosteroids (ICS) in chronic obstructive pulmonary disease: randomised COntrolled trials individual participant Data re-Evaluation. | Manchester University NHS Foundation Trust | GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca |
| 8056 | Ashley Hopkins | Summarising the therapeutic and adverse effects of antibody-drug conjugates in older women with breast cancer: A review of avaliable clinical trial individual-participant data | Flinders University | Roche |
| 8058 | Howard Smith | An individual patient data meta-analysis of clinical endpoints in pulmonary hypertension with interstitial lung disease (PH-ILD) | Pulmonary Vascular Disease Unit, Royal Hallamshire, Sheffield Teaching Hospitals | Boehringer Ingelheim, Johnson & Johnson |
| 8175 | Guoxing Wan | Efficacy and safety of atezolizumab plus bevacizumab for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade | Hubei University of Medicine | Roche |
| 8180 | Sheng Luo | Clinical and molecular characteristics of human epidermal growth factor receptor 2-positive and human epidermal growth factor receptor 2-negative breast cancer | Duke University | Daiichi Sankyo, Inc., Roche, Lilly, Pfizer Inc. |
| 8236 | Gao-Jun Teng | The role of prior transarterial chemoembolization in atezolizumab plus bevacizumab in hepatocellular carcinoma | Zhongda Hospital, Southeast University | Roche |
| 8244 | Frank Doyle | Do psychometrics matter? The effects of advanced psychometric analyses on depression randomised trial outcomes | Royal College of Surgeons Ireland | GlaxoSmithKline, Lilly, Pfizer Inc., Takeda |
| 8263 | George Ntaios | Risk of myocardial infarction in patients with paroxysmal vs. non-paroxysmal atrial fibrillation: an individual patient data meta-analysis | University of Thesaly, Larissa, Greece | Boehringer Ingelheim, Daiichi Sankyo, Inc. |
| 8266 | Shenghong Zhang | The prognostic value of faecal calprotectin for long-term outcomes in ulcerative colitis | The first affiliated hospital of Sun Yat-sen University | Takeda |
| 8287 | Damian J. Ralser | Evaluation of the easy-to-implement modified Glasgow prognostic score (mGPS) in patients with previously treated human epidermal growth factor receptor 2-positive advanced breast cancer in the KATE2 clinical trial | Department of Gynecology and Gynecological Oncology, University Medical Center Bonn (UKB), Bonn, Germany & Institute of Experimental Oncology, University Medical Center Bonn (UKB), Bonn, Germany | Roche |
| 8294 | Neeraj Narula | Extended Validation of an Ulcerative Colitis Vedolizumab Decision Support Tool for Outcome Prediction with Tofacitinib | Hamilton Health Sciences | Pfizer Inc. |
| 8315 | Chiara Tani | Evaluation of gender differences in the efficacy and safety of belimumab in the treatment of active systemic lupus erythematosus | Azienda Ospedaliero Universitaria Pisana, University of Pisa | GlaxoSmithKline |
| 8316 | Vipul Jairath | Correlation Between Symptoms and Objective Measures of Disease Activity in Patients with Moderate to Severe Ulcerative Colitis and Crohn’s Disease | Alimentiv | Pfizer Inc., Takeda, Johnson & Johnson, AbbVie |
| 8324 | Jeroen Dekervel | Response Evaluation Criteria in Solid Tumors (RECIST) vs modified RECIST response durability in advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab | UZ Leuven, Leuven, Belgium | Roche |
| 8325 | Xiaodan Tang | Does scoring method impact estimation of significant individual changes using Patient-Reported Outcomes Measurement Information System (PROMIS) measures? Comparing Classical Test Theory versus Item Response Theory | Northwestern University | AbbVie |
| 8327 | Eva Hoster | Constructing estimands for overall survival within causal frame work for dynamic treatment schemes in oncology: Simulation and a clinical trial example | Department for Medical Information Processing, Biometry, and Epidemiology Ludwig-Maximilian University (LMU) Munich | Roche |
| 8342 | GUS SLOTMAN | IDENTIFYING TOCILIZUMAB-RESPONSIVE COVID-19 PATIENTS FROM COVACTA, EMPACTA, AND REMDACTA RCTS PRE-RANDOMIZATION DATA | INSPIRA HEALTH NETWORK, VINELAND, NJ | Roche |
| 8344 | Xiaoling Shang | A clinical variable based-Nomogram could predict survival for Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide | Shandong University | Roche |
| 8347 | Hong Jae Chon | Thyroid irAE correlated with favorable clinical outcome in patients with advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab | CHA Bundang Medical Center | Roche |
| 8349 | Nqoba Tsabedze | The efficacy of beta-blockers on morbidity and mortality endpoints in black hypertensive patients: A meta-analysis | University of Witwatersrand | GlaxoSmithKline |
| 8377 | Neeraj Narula | Estimating Differences in the Comparison of Outcomes in Clinical Trials for UC Patients using Patient-Level Data and Aggregated Data: Network Meta-Analysis | Hamilton Health Sciences | Takeda, Johnson & Johnson, Pfizer Inc., AbbVie |
| 8427 | Ahmad Abuhelwa | Predictors of exposure, therapeutic and adverse effects of medicines used in the treatment of multiple myeloma | University of Sharjah | Sanofi, Takeda, Johnson & Johnson |
| 8435 | Hui Zheng | Predictors of galcanezumab in the preventive treatment of migraine | Chengdu University of Traditional Chinese Medicine | Lilly |
| 8436 | David Schade | Development of an Atherosclerosis Reversal Calculator | NM Non profit Society to Prevent Symptomatic Heart Disease | AstraZeneca |
| 8438 | Sheng Luo | Development of novel statistical methods to detect treatment effect in Alzheimer’s disease clinical trials over time | Duke University | AbbVie |
| 8440 | David Seiffge | Andexanet alfa and the risk of haematoma expansion in patients with non-traumatic intracerebral haemorrhage – a pooled individual patient data analysis of ANNEXA-4 ICH and TICH-NOAC | Insel Gruppe AG | AstraZeneca |
| 8442 | Yi Lisa Hwa | Better outcomes among multiple myeloma patients who are taking beta-blockers while receiving chemotherapy | Mayo Clinic | Sanofi |
| 8443 | Lane Desborough | Aerobic and Anaerobic Exercise Effects on Blood Glucose and Insulin | Nudge BG, Inc. | Jaeb Center for Health Research Foundation, Inc. |
| 8445 | Kelley Kidwell | Use of external control with longitudinal data for drug evaluation in Duchenne muscular dystrophy: a Bayesian small sample, sequential, multiple assignment randomized trial design (snSMART) | University of Michigan | Cure Duchenne, Lilly |
| 8446 | Elias Eriksson | Efficacy of serotonin reuptake inhibitors in children and adolescents #3 | Neuroscience and physiology | Lilly, GlaxoSmithKline, Pfizer Inc., AbbVie, Lundbeck |
| 8450 | Dennis McGonagle | The effect of Body Mass Index (BMI) and Age on Baricitinib efficacy in Covid-19 patients | Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, NIHR Leeds Musculoskeletal Biomedical Research Unit, Chapel Allerton Hospital, Leeds, UK | Lilly |
| 8542 | João Sérgio Neves | Albiglutide and Cardiovascular Outcomes in Type 2 Diabetes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use | Faculty of Medicine of University of Porto | GlaxoSmithKline |
| 8546 | Alice Adenis | Modeling the impact of physical activity, estimated by sensors such as accelerometers and heart rate, on glycemia of Type 1 Diabetes (T1D) patients. | Diabeloop | Jaeb Center for Health Research Foundation, Inc. |
| 8555 | Gijsbert Stoet | Effects of exercise on blood glucose levels, food intake and insulin use in T1D patients | University of Essex, Colchester, UK | Jaeb Center for Health Research Foundation, Inc. |
| 8557 | Fan Ge | Organ-specific metastatic landscape dissects programmed death ligand-1 (PD-L1) blockade efficacy in advanced cancer | Guangzhou Medical University | Roche, Lilly |
| 8558 | Pablo Guisado Vasco | Investigating the impact of antibodies against SARS-CoV-2 on the effectiveness of interleukin-6 inhibitors in Covid-19 patients | Hospital Universitario Quironsalud Madrid; Universidad Europea (Madrid) | Roche |
| 8559 | Dag Aarsland | Predicting Cognitive Abilities and Treatment Outcome of Major Depressive Disorder in Elderly Patients Using Vortioxetine and Duloxetine Antidepressants | King's College London | Lundbeck |
| 8560 | Emily Fox | Hybrid machine learning modeling of Insulin-Glucose dynamics for T1D | Stanford University | Jaeb Center for Health Research Foundation, Inc. |
| 8562 | Raquibul Hannan | Long-term outcomes of renal cell carcinoma patients with stable disease following treatment with Ipilimumab and Nivolumab in randomized controlled trial Checkmate 214 | UT Southwestern Medical Center | Bristol Myers Squibb |
| 8564 | SANGWOO KIM | Development of Immune Phenotype-specific Immune Checkpoint Inhibitor Response (anti-programmed death ligand-1) Prediction Algorithm | Yonsei Univ. College of Medicine | Bristol Myers Squibb |
| 8569 | GUS SLOTMAN | USING PRE-RANDOMIZATION DATA TO IDENTIFY PATIENTS WITH COVID-19 AMONG WHOM FLUVOXAMINE OR IVERMECTIN IMPROVED OUTCOMES | Inspira Health Network, Vineland, NJ | Platform Life Sciences |
| 8576 | Dafne Capelusnik | Validating a Personalised Ankylosing Spondylitis Metrology Index | Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, the Netherlands | AbbVie, Johnson & Johnson, Pfizer Inc., UCB, Lilly |
| 8577 | Yao Zhu | The impact of long-term proton pump inhibitors use on the prognosis of patients receiving Androgen-annihilation therapy | Fudan University Shanghai Cancer Center | Bayer |
| 8581 | Masahiro Takeuchi | Repositioning of neurological drug Aripiprazole for Amyotrophic lateral sclerosis (ALS) patients | The University of Tokyo | Otsuka Pharmaceuticals |
| 8582 | David Cherney | Modelling Studies to Assess Sodium-Glucose co-Transporter-2 (SGLT2) Inhibition Effects and Kidney Protection in Type 1 Diabetes | University Health Network | AstraZeneca, Boehringer Ingelheim |
| 8585 | Daniel Schachter | Efficacy of CGRP monoclonal antibodies in the treatment of medication overuse headache in patients with chronic migraine: A systematic review and meta-analysis | Unigranrio | Lilly, Lundbeck |
| 8588 | Wenlong Zhong | The influence of antibiotics on survival outcomes for bladder cancer patients being treated with immune checkpoint inhibitor therapy | Sun Yat-sen Memorial Hospital of Sun Yat-sen University（SYSU） | Roche |
| 8591 | John Reynolds | Patterns of skin flare in patients with systemic lupus erythematosus | University of Birmingham | AstraZeneca |
| 8593 | Hyon Choi | Serum urate reduction, gout flares and risk of major cardiovascular events during urate-lowering therapy initiation: target trial emulation and self-controlled case series analysis | Massachusetts General Hospital | Takeda |
| 8599 | Marliese Alexander | Clinical factors predictive of survival outcomes in patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer | Peter MacCallum Cancer Centre | Takeda, Roche, Pfizer Inc. |
| 8602 | Robert Hamilton | Statin use and prostate cancer outcomes in patients treated in the ARAMIS trial | Princess Margaret Cancer Center, University of Toronto | Bayer |
| 8603 | Wencai Jiang | Predictive value of high‐sensitivity cardiac troponin‐T for Major Adverse Cardiovascular Events in patients with Chronic coronary heart disease | Chengdu Second People's Hospital | GlaxoSmithKline |
| 8606 | Daria Igudesman | Eating duration, frequency, and distribution of nutrient intake in association with glycemia, adiposity, and sleep | AdventHealth Translational Research Institute | Jaeb Center for Health Research Foundation, Inc. |
| 8609 | Fredrik Schjesvold | Personalized prediction of progression-free survival in multiple myeloma patients treated with isatuximab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone only, using combined machine learning and mechanistic modeling. | Oslo University Hospital | Sanofi |
| 8611 | Adam de Havenon | Index Stroke Severity in Secondary Prevention Trials | Yale University | Boehringer Ingelheim |
| 8615 | Monia Rekik | Using artificial intelligence to predict and prevent physical activity induced hypoglycemia and hyperglycemia in type 1 diabetes | Université Laval | Jaeb Center for Health Research Foundation, Inc. |
| 8656 | Meg Jardine | The RAAS inhibition in COVID-19 Trialists Collaboration | The University of Sydney | University of Minnesota, Bassett Medical Center |
| 8684 | José da Silva | 3Variable and 4Variable Boolean-based remission with Tofacitinib and their association with radiographic outcomes in rheumatoid arthritis | Centro Hospitalar e Universitário de Coimbra | Pfizer Inc. |
| 8686 | Andrea E. van der Meulen - de Jong | Anemia and therapy with Janus Kinase Inhibitors in patients with ulcerative colitis | Leiden University Medical Center | Pfizer Inc. |
| 8688 | Grace Lu-Yao | Risk of therapy-related adverse events in men on abiraterone or enzalutamide, a IPD meta-analysis of clinical trial data | Thomas Jefferson University | GlaxoSmithKline, Sanofi, Johnson & Johnson |
| 8699 | Niklas Klümper | Evaluation of baseline and on-treatment serum biomarkers to predict immunotherapy response in solid cancers | Department of Urology and Pediatric Urology, University Medical Center Bonn (UKB) | Roche |
| 8700 | Leo Buckley | Colchicine Adverse Effects Research in people with Covid-19 randomized to colchicine treatment | Brigham and Women's Hospital | Montreal Heart Institute |
| 8712 | Arthur Mikhno | T1-DEXI Analysis for Exercise Study | Medtronic Foundation | Jaeb Center for Health Research Foundation, Inc. |
| 8716 | Ali Cinar | Data Analysis, Classification and Model Development using CGM and Physical Activity Data of people with Type 1 Diabetes | Illinois Institute of Technology | Jaeb Center for Health Research Foundation, Inc. |
| 8720 | George Ntaios | Association between statin treatment and risk of cardiovascular outcomes and death in patients with atrial fibrillation: an individual patient data meta-analysis | University of Thessaly, larissa, Greece | Daiichi Sankyo, Inc., Boehringer Ingelheim |
| 8721 | Jorge Bondia | Modeling of exercise and meal disturbances under free-living conditions for improved performance of single- and dual-hormone artificial pancreas systems | Universitat Politècnica de València | Jaeb Center for Health Research Foundation, Inc. |
| 8722 | Daniele Robesti | Assessing the Androgen indifferent prostate cancer patients reponse to novel antiandrogen-based regimen or taxanes. | IRCCS Ospedale San Raffaele | Johnson & Johnson, Sanofi |
| 8724 | Joel Skaistis | Effect of Tafamidis on Dementia Medication Initiation: A Post-Hoc Analysis of the ATTR-ACT Trial | Corewell Health | Pfizer Inc. |
| 8728 | Glen Hazlewood | Disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis incorporating individual patient data | University of Calgary | AbbVie, Lilly, UCB, Roche, Pfizer Inc., Johnson & Johnson, Sanofi |
| 8729 | Octavian Adam | Time to Initiation of Symptomatic Treatment in untreated Parkinson Disease | Albany Medical College | Biogen |
| 8747 | Arsalan Shahid | Unlocking the Secrets of Glucose Variability: A Machine Learning and Data-Driven Analysis of Hypoglycemia and Hyperglycemia | CeADAR: Ireland's Centre for Applied AI at University College Dublin | Jaeb Center for Health Research Foundation, Inc. |
| 8750 | Manit Srisurapanont | Depressive Symptoms Responding to Bupropion: A Differential Item Functioning Approach in Patients with Major Depressive Disorder | Chiang Mai University Faculty of Medicine | GlaxoSmithKline |
| 8751 | Diederik Dippel | Prediction of the treatment benefit of intravenous alteplase treatment for acute ischemic stroke | Erasmus MC University Medical Center | Boehringer Ingelheim |
| 8752 | Michelle Condren | Helmsley Charitable Trust RFP | University of Oklahoma | Jaeb Center for Health Research Foundation, Inc. |
| 8753 | Yu-Han Chiu | Dabigatran versus Warfarin in Patients with Atrial Fibrillation: Extending inference from the RE-LY trial to real world target population. | Harvard T.H. Chan School of Public Health | Boehringer Ingelheim |
| 8756 | Eyal Dassau | Evaluation of Assessment of insulin utilization in people with type 1 diabetes mellitus using glucose excursions, insulin delivery metrics, and combined with nutrition and exercise information from the T1-DEXI dataset | Eli Lilly and Company | Jaeb Center for Health Research Foundation, Inc. |
| 8757 | Sandra Tessa Hattenhauer | Baseline immune signature score as predictor for response immunotherapy in HCC | Medical Clinic III for Hematology, Oncology, Immune-Oncology, Rheumatology, University Hospital Bonn | Roche |
| 8758 | Michael Szarek | Comparison of RGX-202-01 with ramucirumab or aflibercept in the treatment of patients with recurrent colorectal cancer harboring a RAS mutation | CPC Clinical Research | Lilly, Sanofi |
| 8760 | Florian Naudet | Tolerability of duloxetine in the elderly and in younger adults: a systematic review and individual patient data meta-analysis of randomized controlled trials versus placebo. | CHU Rennes, Clinical Investigation Center INSERM 1414, Department of clinical pharmacology and Adult Psychiatry | Lilly, Pfizer Inc., Lundbeck, Takeda, AbbVie |
| 8764 | Giuseppe Cabibbo | Competing risk factors in survival analyses for advanced hepatocellular carcinoma outcomes. The key role of liver function and impact of drug class | University of Palermo | Roche |
| 8765 | Amit Etkin | Understanding individual differences in response to roflumilast in schizophrenia | Alto Neuroscience | AstraZeneca |
| 8766 | Catherine Russon | Using machine learning methods to predict the risk of exercise-induced hypoglycemia in people with Type 1 diabetes | Exeter Centre of Excellence for Diabetes Research (EXCEED), University of Exeter | Jaeb Center for Health Research Foundation, Inc. |
| 8767 | Armando Turchetta | Forecasting recruitments in multicenter clinical trials via the time-dependent Poisson-Gamma model | McGill University | Roche |
| 8768 | Ryan Mizell | Predicting progression in Primary Progressive Multiple Sclerosis with Machine Learning | Advent Health | Roche |
| 8769 | Hyung Seok Park | A novel prediction model of poly ADP ribose polymerase (PARP) inhibitor sensitivity using genomic analyses | Yonsei University College of Medicine, Cancer Prevention Center, Yonsei Cancer Center | Pfizer Inc. |
| 8773 | Roxana Mehran | Antithrombotic therapy in patients with atrial fibrillation after percutaneouscoronary intervention: a systematic review and individual patient data network meta-analysis Revision of 6118 | The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA | Boehringer Ingelheim, Daiichi Sankyo, Inc., Bristol Myers Squibb |
| 8774 | Paco Welsing | Using the “potential-outcomes framework” to predict added value of more intensive initial therapy for individual early Rheumatoid Arthritis (RA) patients | Dept of Rheumatology & Clinical Immunologie, University Medical Center Utrecht | Roche |
| 8802 | Zhi Xiao | Roles of neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) in prognosis in HER2-positive breast cancer with trastuzumab and pertuzumab therapy | Xiangya Hospital, Central-South University | Roche |
| 8803 | Temiloluwa Prioleau | T1-DEXI Analytics | Emory University | Jaeb Center for Health Research Foundation, Inc. |
| 8806 | Timothy Gaulton | Obesity and COVID-19 | Mass General Hospital, Harvard Medical School | Lilly, NIAID (a data-sharing platform funded by the National Institutes of Health) |
| 8809 | Jing Yu | Constructing a predictive model for lung cancer immunotherapy | Sichuan university | Tempus AI, Inc. |
| 8815 | Rayid Abdulqawi | Effect of Calcium Channel Blocker Therapy in Idiopathic Pulmonary Fibrosis | King Faisal Specialist Hospital and Research Centre | Roche, Boehringer Ingelheim |
| 8828 | Christopher Moxon | Comparison of histophathology in fatal Covid-19 in Malawi with fatal cases in other settings | University of Glasgow | Hannover Medical School |
| 8833 | Derek Dinart | Optimal estimation of the number of subjects in clinical trials to improve the quality of clinical research and the development of new treatments for cancer patients | University of Bordeaux, INSERM U1219 & Institut Bergonié | Sanofi, Roche, Lilly, Pfizer Inc., Boehringer Ingelheim |
| 8834 | Xiaohua Douglas Zhang | Markers derived from continuous glucose monitoring data to guide exercise for T1DM | University of Kentucky | Jaeb Center for Health Research Foundation, Inc. |
| 8837 | Erin Tallon | Development of an mHealth-Based Just-In-Time Adaptive Intervention (JITAI) for Promoting Physical Activity in Individuals with Type 1 Diabetes | Children's Mercy Kansas City | Jaeb Center for Health Research Foundation, Inc. |
| 8839 | Florencia Tettamanti | Predicting survival in chronic lymphocytic leukaemia from measurable residual disease (MRD) kinetics | AstraZeneca | Roche |
| 8842 | Sheng Luo | Clinical and molecular characteristics of hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) breast cancer: a meta-analysis | Duke University | Roche, Pfizer Inc., AstraZeneca |
| 8845 | Shenghong Zhang | Biomarkers for predicting long-term outcomes in ulcerative colitis | The first affiliated hospital of Sun Yat-sen University | Takeda, AbbVie, Johnson & Johnson |
| 8846 | Charles Horsburgh | Predictors of Emergence of Drug Resistance While on Treatment for MDR-TB: A Meta-Analysis | Boston University School of Public Health | Otsuka Pharmaceuticals |
| 8848 | Wenrui Hao | Develop a mathematical model for Alzheimer's disease virtual clinical trial | Penn State University | Lilly |
| 8850 | Changsheng Ma | The impact of malnutrition on the Efficacy and Safety of empagliflozin for people with heart failure | Beijing Anzhen Hospital | Boehringer Ingelheim |
| 8853 | Guang Sheng Ling | Using clinical characteristics of hepatocellular carcinoma (HCC) patients as predictors of their immunotherapy response | University of Hong Kong (HKU) Li Ka Shing Faculty of Medicine | Roche |
| 8856 | Fei Ma | The impact of human epidermal growth factor receptor 2-low (HER2-low) Expression on the Efficacy of endocrine therapy in Hormone Receptor-positive/HER2-Negative (HR+/HER2-) Breast Cancer | Chinese Academy of Medical Sciences and Peking Union Medical College | Project Data Sphere, Pfizer Inc., Roche, AstraZeneca, Sanofi |
| 8857 | Zachary Epstein-Peterson | A phase 2 study of Cerdulatinib in treating Cutaneous T-cell Lymphoma (CTCL). | Memorial Sloan Kettering Cancer Center | AstraZeneca |
| 8860 | Yutaka Shimazu | Pretreatment lymphocyte counts and free light chain ratio predict the efficacy of elotuzumab against relapsed/ refractory multiple myeloma | Kyoto Innovation Center for Next Generation Clinical Trials and iPS Cell Therapy (Ki-CONNECT), Kyoto University Hospital | Bristol Myers Squibb |
| 8864 | Lisa Chow | Machine Learning to evaluate glycemic variation with exercise | University of Minnesota | Jaeb Center for Health Research Foundation, Inc. |
| 8865 | Erin Tallon | Data driven approaches to inform the development of eating behavior patterns that promote glycemic management in youth with type 1 diabetes | Children's Mercy Kansas City | Jaeb Center for Health Research Foundation, Inc. |
| 8866 | Marc Breton | Exercise Patterns Informing Automated Insulin Delivery Systems | University of Virginia | Jaeb Center for Health Research Foundation, Inc. |
| 8873 | Cristina Soguero Ruiz | Multimodal data-driven analysis of T1D in pediatrics and adults with machine learning | King Juan Carlos University | Jaeb Center for Health Research Foundation, Inc. |
| 8874 | Nicola Dalbeth | An investigation of remission in patients with gout - efficacy of treatments, prediction of remission and outcomes | University of Auckland | Takeda |
| 8877 | Cinzia Del Giovane | Antithrombotic therapies for secondary prevention in patients with cryptogenic stroke: a systematic review and network meta-analysis with individual participant data | University Hospital of Modena and Reggio Emilia, Modena, Italy | Boehringer Ingelheim, Sanofi, Daiichi Sankyo, Inc. |
| 8879 | Micaela Morettini | Development of a decision support solution to prevent hypoglycemia during and after exercise in T1D | Università Poiltecnica delle Marche | Jaeb Center for Health Research Foundation, Inc. |
| 8884 | Haotian Zou | Risk stratification model for predicting risk of recurrence in human epidermal growth factor receptor 2 (HER2) positive breast cancer patients with pathological complete response after neoadjuvant therapy | Department of Biostatistics and Bioinformatics, Duke University School of Medicine | Roche |
| 8885 | Giacomo Cappon | ReplayBG-E: Expansion of the ReplayBG software to assess exercise-aware treatments of type 1 diabetes | University of Padova, Department of Information Engineering (DEI) | Jaeb Center for Health Research Foundation, Inc. |
| 8889 | Fabricio Garelli | Modelling short and long-term exercise effect on glucose levels from wearable devices’ signal patterns. | National University of La Plata and CONICET. | Jaeb Center for Health Research Foundation, Inc. |
| 8890 | Konrad Mulrennan | DEXTER - Diabetes Exercise Training for Enhanced Regulation | Atlantic Technological University | Jaeb Center for Health Research Foundation, Inc. |
| 8892 | Eleonora Maria Aiello | Exercise timing and Circadian Rhythms | University of Trento | Jaeb Center for Health Research Foundation, Inc. |
| 8893 | Eleonora Manzoni | Detection and prediction of physical activity in type 1 diabetic subjects | University of Padova | Jaeb Center for Health Research Foundation, Inc. |
| 8896 | Bin Cao | Treatment of baloxavir marboxil in immunocompromised patients with influenza infection | China-Japan Friendship Hospital | Roche |
| 8897 | Rebecca Dean | The impact of interventions for depression on self-perceptions in young people: A systematic review and meta-analysis | University of Sussex | GlaxoSmithKline |
| 8903 | Daniel DeSalvo | DeSalvo - BCM Helmsley RFP Improving Exercise With T1D | Baylor College of Medicine | Jaeb Center for Health Research Foundation, Inc. |
| 8913 | Thomas Hawke | T1-DEXi-T Study: Does exercise training improve the time in range following acute bouts of exercise? | McMaster University | Jaeb Center for Health Research Foundation, Inc. |
| 8921 | Sheng Luo | The efficacy of programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors in solid tumor patients with different clinicopathological characteristics: a meta-analysis | Duke University | Daiichi Sankyo, Inc., Roche |
| 8922 | Tomas Koutny | In-Silico modelling | University of West Bohemia | Jaeb Center for Health Research Foundation, Inc. |
| 8924 | Prajakta Belsare | Analyzing exercise settings and the impact of various intensities, durations, and types of exercise on people with Type 1 diabetes. | James Madison University | Jaeb Center for Health Research Foundation, Inc. |
| 8926 | Alessio Cortellini | The putative differential impact of opioids exposure in patients with advanced non-small cell lung cancer (NSCLC) treated with immunotherapy or chemotherapy: a post-hoc analysis of the randomized phase 2 POPLAR and phase 3 OAK trials. | Department of Surgery and Cancer, Imperial College London, London, UK | Roche |
| 8933 | João Pedro Ferreira | Non cardiovascular hospitalizations in heart failure and preserved ejection fraction (HFpEF) and the effect of empagliflozin | Faculty of Medicine of the University of Porto | Boehringer Ingelheim |
| 8937 | Cosima Locher | Predictors of placebo response in opioid trials for patients with Chronic Primary Pain – An individual-patient data meta-analysis | University Hospital Zurich of the University of Zurich, Switzerland | Pfizer Inc., AbbVie |
| 8944 | Wesley Kerr | Evaluation of Time to Event endpoints in randomized controlled trials of multiple antiseizure medications for uncontrolled epilepsy | University of Pittsburgh | GlaxoSmithKline, Johnson & Johnson, UCB |
| 8946 | Stuart Pocock | Patterns of heart failure hospitalisations and cardiovascular death in EMPEROR studies | London School of Hygiene and Tropical Medicine | Boehringer Ingelheim |
| 8953 | Wilson Lin | Drivers of Algorithm/Technology Use In Type 1 Diabetes Self-Management | Santa Clara University | Jaeb Center for Health Research Foundation, Inc. |
| 8956 | Sheng Luo | A Novel Machine Learning-Based Prediction Model for Outcomes in Patients with previously Untreated Diffuse Large B Cell Lymphoma | Duke University | Roche, Project Data Sphere |
| 8957 | Dean Bodenham | Two-sample testing for clinical trials data with missing values | Imperial College London | Bayer |
| 8966 | Alberico L. Catapano | Effect of lipid-lowering therapies on lipoprotein(a) levels: a meta-analysis of randomized controlled trials | IRCCS MultiMedica | Sanofi |
| 8985 | Joel Skaistis | Effect of tafamidis treatment on total cardiovascular and cerebrovascular events in Transthyretin (TTR) cardiac amyloidosis | Corewell Health | Pfizer Inc. |
| 8997 | Lewis Carpenter | The integration of clinical trial data, real-world evidence, and novel statistical methods to optimise control arm recruitment in relapsed and refractory multiple myeloma | Arcturis | Sanofi |
| 9004 | Limin Zhao | Predicting which breast cancer patients will benefit from Palbiclib treatment through a machine learning model | Nan Chang University | Pfizer Inc. |
| 9007 | Zhao Xingwang | Prediction of hypoglycemia during and after exercise | Jilin University | Jaeb Center for Health Research Foundation, Inc. |
| 9012 | Barry Greenberg MD | Development of a Machine Learning Based Score to Predict Risk of Sudden Cardiac Death in Patients with Heart Failure with Preserved Ejection Fraction | University of California, San Diego | Boehringer Ingelheim |
| 9016 | Alane Izu | Evaluation of Immune Response of 10-valent Pneumococcal Conjugate Vaccine (PCV-10) in HIV infected and uninfected children | WITS-VIDA | GlaxoSmithKline |
| 9018 | Alessio Cortellini | Differential effect of systemic antibiotics and proton pump inhibitors on clinical outcomes from immunotherapy or placebo as sequential therapy in patients with locally advanced, unresectable non-small cell lung cancer (stage III) who have not progressed following chemoradiation therapy: A post-hoc analysis of the PACIFIC trial. | Department of Surgery and Cancer, Imperial College London (UK) | AstraZeneca |
| 9019 | Philip Johnson | Assessing the validity of progression-free survival as an endpoint in clinical trials | University of Liverpool | Roche, Boehringer Ingelheim, GlaxoSmithKline, Sanofi, AbbVie |
| 9024 | Alain Amstutz | Effectiveness and safety of janus kinase inhibitors in hospitalized patients with COVID-19: Systematic review and individual patient data meta-analysis of randomized trials | Division Clinical Epidemiology, Department Clinical Research, University Hospital Basel | Lilly, IDDO, NIAID (a data-sharing platform funded by the National Institutes of Health) |
| 9053 | Johanna Elin Gehin | Personalised dosing of certolizumab pegol based on serum concentration in rheumatoid arthritis | Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway | UCB |
| 9076 | Alexander Tolmach | Automatic nutrition assessment based on glucose and insulin data for improvement of carbs counting and investigation of glycemia episodes | MakeSense Digital Health Ltd. | Jaeb Center for Health Research Foundation, Inc. |
| 9077 | Anne-Marie Wills | Predictors of Progressive Supranuclear Palsy (PSP) disease progression | Massachusetts General Hospital | AbbVie |
| 9081 | Kyle Greenway | Antidepressant effects of bupropion, varenicline, nicotine replacement therapy, and placebo in tobacco users. | McGill University | Pfizer Inc. |
| 9090 | Lena Friberg | Dose-exposure-response relationships for ceftazidime-avibactam of value to explore dose individualization strategies | Uppsala University | Pfizer Inc. |
| 9093 | Ewan Goligher | Secondary analysis for estimating heterogeneous treatment effects for the “Drotrecogin Alfa (Activated) in Adults with Septic Shock” trial | Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Ontario, Canada | Lilly |
| 9098 | Stéphane Oudard | External validation of a prognostic score for survival in patients with metastatic castration-resistant prostate cancer (CABASCORE) treated with Cabazitaxel. | Assitance Publique des Hôpitaux de Paris | Sanofi |
| 9099 | Andrew Sims | An exploration of UK real world evidence and comparison with clinical trial data in supporting evaluation of 4 drugs that have exited the United Kingdom’s Cancer Drugs Fund (CDF). | Newcastle upon Tyne Hospitals NHS Trust | Takeda, Bristol Myers Squibb |
| 9102 | Joel Skaistis | Effect of Tafamidis Across the Range of Systolic Function: A Post-Hoc Analysis of the ATTR-ACT Trial | Corewell Health East | Pfizer Inc. |
| 9103 | JOSE GARCIA-TIRADO | Meal and physical activity behavior in people with type 1 diabetes. A retrospective analysis. | University of Bern | Jaeb Center for Health Research Foundation, Inc. |
| 9104 | Mark Woodward | January AI T1D | January AI | Jaeb Center for Health Research Foundation, Inc. |
| 9105 | Nate Kowahl | Verily_Analysis | Verily Life Sciences | Jaeb Center for Health Research Foundation, Inc. |
| 9106 | Nima Aghaeepour | Identifying Subgroups of Patients with Improved Outcomes in Clinical Trials | Stanford University | Takeda, AbbVie, Daiichi Sankyo, Inc., Lilly, AstraZeneca, Roche, Sanofi, Pfizer Inc., Montreal Heart Institute, Duke University School of Medicine/Duke University Hospital |
| 9121 | Vitalay Fomin | Biomarkers associated with response to monotherapy compared to combination therapy in cancers | Y-AI inc. | Roche |
| 9128 | Pierluigi Navarra | A comparison between the assessments of overall response rate carried out by local assessors and a blinded independent central review in oncology trials. Analysis of differences in the assessment conducted at single-patient level. | Catholic University Medical School, Rome, Italy | Roche |
| 9129 | Yi-Wen Tsai | Cost-effectiveness analysis of atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: subgroups analyses | Institute of Health & Welfare Policy, National Yang Ming Chiao Tung University | Roche |
| 9130 | Feng Sun | An individual participant data meta-analysis to evaluate new hypoglycemic drugs (SGLT-2i and DPP-4i) on type 2 diabetes mellitus patient sub-groups | School of public health, Peking University | Boehringer Ingelheim, Takeda |
| 9132 | Viola Pongratz | Monitoring of upper extremity motor function in Multiple Sclerosis (MS): the nine-hole-peg-test in MS revisited | Technical University Munich, School of Medicine, Neurology | Biogen, Roche, Sanofi |
| 9137 | Ly-Mee Yu | Loop Diuretics and Weight Change in Heart Failure: A Meta-Analysis | Nuffield Department of Primary Care Health Sciences, University of Oxford | Boehringer Ingelheim, Bayer, GlaxoSmithKline |
| 9141 | Shujie Yang | Fatty Acid Metabolism, Oxidative phosphorylation, and cholesterol homeostasis pathways in endometrial cancer organoids | university of Iowa | Tempus AI, Inc. |
| 9228 | Kenta Yoshida | Tumor Growth Inhibition-Overall Survival (TGI-OS) model development for hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer | Genentech/Roche | Pfizer Inc., AstraZeneca |
| 9229 | Andreas Meid | MAGIC-BULLET - Model-based support of translational steps throughout drug development of antibody-drug conjugates (ADCs) in breast cancer | Heidelberg University Hospital, Dept. of Clinical Pharmacology & Pharmacoepidemiology, Im Neuenheimer Feld 410 , 69120 Heidelberg, Germany | Roche, Daiichi Sankyo, Inc. |
| 9230 | Erinne Wasalski | Health-Related Quality of Life in Breast Cancer Clinical Trials Through the Lens of Race and Ethnicity: The Importance of Understanding the Patient Experience | Rutgers University | Pfizer Inc., Roche, Lilly, Boehringer Ingelheim, Daiichi Sankyo, Inc., AstraZeneca |
| 9234 | Matthew Chersich | Developing data science solutions to mitigate the health impacts of climate change in Africa: The Heat and Health African Transdisciplinary Center (HE²AT Center) | Wits Reproductive Health Institute at University of the Witwatersrand - Climate and Health Directorate | Boehringer Ingelheim, Sanofi |
| 9235 | Christian Lood | Neutrophil Lymphocyte Ratio as predictor of treatment response in malignancy | University of Washington | Lilly |
| 9236 | Christian Dansereau | Validation of prognostic machine learning tools for forecasting clinical progression to enrich Alzheimer’s disease trials | Perceiv AI | Lilly, AbbVie, Takeda |
| 9239 | Sheng Luo | Impact of Clinical and Molecular Characteristics of Lymphoma Patients on Prognosis and Potential Mechanisms | Duke University | Roche, GlaxoSmithKline, Takeda |
| 9240 | Michael Kreissl | "Parameters of Body Composition as prognostic biomarkers in patients with RET-altered thyroid cancer treated with selpercatinib" Post-hoc analysis of the LIBRETTO-001 trial | University Hospital Magdeburg | Lilly |
| 9241 | Amit Garg | Association between skin-related quality of life and race in patients with hidradenitis suppurativa, and Repeatability/Intra-rater agreement of lesion counts in hidradenitis suppurativa | Department of Dermatology, Northwell Health, New Hyde Park, NY | AbbVie |
| 9244 | Kazuki Takada | Impact of Probiotics on Clinical Outcomes in Patients with Extensive-Stage Small-Cell Lung Cancer Treated with First-Line Atezolizumab Combination Therapy: A Post Hoc Analysis of IMpower133 | Saiseikai Fukuoka General Hospital, Fukuoka, Japan | Roche |
| 9247 | Giovanni Sebastiani | Hypoglicaemic events risk prediction for type 1 diabetes subjects during physical activity | Italian National Council of Research, Institute for Applied Mathematics "Mauro Picone" | Jaeb Center for Health Research Foundation, Inc. |
| 9250 | Nan Hu | Machine learning augmented decision support system for myocardial revascularization treatment plan selection | Florida International University | Duke University School of Medicine/Duke University Hospital |
| 9252 | Danny Volkaerts | Smart Diabetes Assistent | University Colleges Leuven-Limburg, association of Catholic University Leuven, Belgium | Jaeb Center for Health Research Foundation, Inc. |
| 9253 | Jiajun Yan | Statistical Methods for Analyzing EuroQol 5 Dimension 5 (EQ-5D) in Randomized Clinical Trials | McMaster University, Hamilton, Ontario, Canada | Lilly, Takeda, AbbVie, Biogen, Sanofi, Pfizer Inc. |
| 9274 | Kazuki Takada | Prognostic Impact of Probiotic Supplementation on the Outcomes in Patients with Advanced Non-Small Cell Lung Cancer Treated with First-Line Atezolizumab: Pooled Analyses of Five Randomized Control Trials | Saiseikai Fukuoka General Hospital, Fukuoka, Japan | Roche |
| 9275 | Kazuki Takada | Influence of Acetaminophen on Treatment Outcomes in Advanced Non-Small Cell Lung Cancer: Pooled Data Analyses from Five Randomized Control Trials of First-Line Atezolizumab | Saiseikai Fukuoka General Hospital, Fukuoka, Japan | Roche |
| 9280 | Nuno Filipe de Sousa Vale | Population Pharmacokinetic Study involving different formulations of Salbutamol | Faculty of Medicine, University of Porto | GlaxoSmithKline |
| 9284 | Jiro McKinnis | Associative Analysis of Comorbidities and Clinical Variables with Concomitant Presence of Congestive Heart Failure (CHF) in Patients Undergoing Cardiac Catheterization | Virror Health | Duke University School of Medicine/Duke University Hospital |
| 9285 | Mengyi Lu | Association of Body Mass Index (BMI) with Prognosis and Safety Profile of Atezolizumab | Nanjing Medical University | Roche |
| 9286 | João Sérgio Neves | Effect of Exenatide Across the Spectrum of Ejection Fraction: An analysis from the EXSCEL trial | Faculdade de Medicina da Universidade do Porto | AstraZeneca |
| 9328 | Sebastian Polak | Developing a quantitative base for more effective and individualized ropinirole dosing regimen | Faculty of Pharmacy, Jagiellonian University Medical College in Poland | GlaxoSmithKline |
| 9332 | Neeraj Narula | Outcomes from Induction Using Ustekinumab or Vedolizumab Among Patients Who Have Prior Biologic Intolerance vs Biologic Failure in Ulcerative colitis and Crohn's disease | Hamilton Health Sciences | Johnson & Johnson, Takeda |
| 9350 | Lucy Vivash | Evaluation of epilepsy-DOOR (Desirability of outcome ranking) as an outcome measure for therapeutic trials in drug resistant epilepsy | Monash University | UCB |
| 9352 | Sangwoo Kim | Conventional genomic predictive markers to immune checkpoint inhibitors are deteriorated in metastatic clear cell renal cell carcinoma | Yonsei University | Bristol Myers Squibb |
| 9354 | Li-Xuan Qin | Tumor Mutational Burden (TMB) Dichotomization for Immunotherapy Outcome Prediction | Memorial Sloan Kettering Cancer Center | Tempus AI, Inc. |
| 9360 | Guilherme Polanczyk | Moderators of treatment response to stimulants in preschoolers with attention-deficit/hyperactivity disorder: an individual patient data meta-analysis | University of Sao Paulo (USP) | Takeda |
| 9373 | Amit Etkin | Cognitive factors as predictors of treatment outcomes in patients with Schizophrenia | Alto Neuroscience, Inc. | Boehringer Ingelheim |
| 9377 | Benjamin Haibe-Kains | Biomarker discovery for immunotherapy response via pan-cancer and cancer-specific analyses | Princess Margaret Cancer Centre, University Health Network | Bristol Myers Squibb |
| 9383 | João Pedro Ferreira | Anemia and the Effect of Empagliflozin in HFpEF: findings from EMPEROR-Preserved | Faculty of Medicine of Porto University | Boehringer Ingelheim |
| 9384 | Evyn Peters | Episode duration and severity as predictors of response to desvenlafaxine and placebo in patients with major depressive disorder | University Of Saskatchewan | Pfizer Inc. |
| 9388 | Ritu Lal | A Prospective Machine Learning Model for the Identification of Sepsis Endotypes | GEn1E Lifesciences Inc. | Lilly |
| 9389 | Sinbad Xia | Predictors of survival in patients with extensive-stage small-cell lung cancer | The Clinical Research Center for Respiratory Diseases of Zhejiang Province, Department of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine | Roche |
| 9390 | Joseph Merola | Musculoskeletal Symptoms in Hidradenitis Suppurativa | The International Dermatology Outcome Measures Group (IDEOM) | AbbVie |
| 9399 | Philip Johnson | A novel, evidence-based approach to clinical trial design in patients with advanced liver cancer (hepatocellular carcinoma); single arm studies with a virtual control group | University of Liverpool | Roche, Boehringer Ingelheim, Bayer, Sanofi, GlaxoSmithKline |
| 9407 | Josep Vehi | Validation of new exercse models and therapy optimization | University of Girona | Jaeb Center for Health Research Foundation, Inc. |
| 9410 | Abhinav Sharma | Proprotein convertase subtilisin/kexin type 9 (PCSK9) Inhibitors on Cardiovascular and Heart Failure Outcomes | The Research Institute of the McGill University Health Centre | Pfizer Inc. |
| 9417 | Vipul Jairath | Determining Endoscopic Treatment Response in Ulcerative Colitis and Crohn’s Disease using the Win Probability Approach | Alimentiv Inc. | Johnson & Johnson, AbbVie, Takeda, Pfizer Inc. |
| 9422 | James Salsbury | Developing methodology for a delayed treatment effect present in a survival trial | University of Sheffield | Roche, Bristol Myers Squibb |
| 9433 | Yang Li | A new Statistical method to balance Social Network Effect and Covariate Effect in Response Adaptive Design | School of Statistics, Renmin University of China | GlaxoSmithKline |
| 9434 | Victor Moreno | Retrospective analysis of different doses of atezolizumab in patients with advanced solid tumors | Victor Moreno, Director of START Madrid-Fundacion Jimenez Diaz (FJD) | Roche |
| 9462 | Chandra Kanth Nagesh | Analysis-of-Type-1-Diabetes | University of Colorado Boulder | Jaeb Center for Health Research Foundation, Inc. |
| 9470 | Joseph Cafazzo | Can we trust GPT-4 Turbo Vision to estimate carbohydrate and caloric content from food images within the broad context of diabetes? | Toronto General Hospitable Research Institute, University Health Network | Jaeb Center for Health Research Foundation, Inc. |
| 9474 | Daniel Adam Blanco | Comparative Analysis of Health-Related Quality of Life in Pulmonary Embolism Survivors: PEmb-QoL versus EQ-5D Instruments | Inari Medical, Inc. | Daiichi Sankyo, Inc. |
| 9478 | Lena Friberg | Study on impact of scanning intervals of follow up tumor assessments on Progression Free Survival (PFS) and median PFS for Non-Small Cell Lung Cancer (NSCLC) patients treated with Atezolizumab and Docetaxel. | Uppsala University | Roche |
| 9480 | Jian-Guo Zhou | Longitudinal peripheral blood markers and patient reported outcomes(PROs) as dynamic predictors to identify efficacy and safety of non–small-cell lung cancer (NSCLC) patients treated with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) | The Second Affiliated Hospital of Zunyi Medical University | Roche, AstraZeneca, Lilly |
| 9481 | Nathalie Germain | Melatonin and melatonin receptor agonists for the treatment of sleep disturbances associated with neurocognitive disorders. | Universite Laval | Takeda |
| 9492 | David McAllister | Understanding frailty, multimorbidity and renal failure in clinical trials: Attrition, retention and heterogeneity of treatment effects in trials for diabetes, cancer and a heterogenous set of index conditions | University of Glasgow | Takeda, AstraZeneca, Boehringer Ingelheim, Johnson & Johnson, Lilly, GlaxoSmithKline, Roche, UCB, Sanofi |
| 9731 | Carl Turesson | Efficacy and safety of TNF inhibitors in seronegative rheumatoid arthritis (update) | Lund University | Johnson & Johnson, Lilly, AbbVie, UCB, Pfizer Inc., Roche |
| 9734 | James Brorson | Merging data from acute stroke secondary prevention trials for analysis of stroke recurrence risks | The University of Chicago | AstraZeneca |
| 9735 | Edouard Auclin | Prognostic and predictive value of the lung immune prognostic index in patients with advanced small cell lung cancers treated with immune checkpoint inhibitors | Institut Bergonié | AstraZeneca, Roche |
| 9736 | Stefan Leucht | Sex differences in antipsychotic side-effects and efficacy in adults with acute exacerbations ofschizophrenia: an individual-participant network meta-analysis | Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, School of Medicine and Health, Technical University of Munich | Lilly, Servier , Johnson & Johnson, GlaxoSmithKline, AbbVie |
| 9738 | Onyekachukwu Illoh | Translating Causal Inferences from Randomized & Single-Arm Trials to Externally-Controlled Trials | University of Maryland, Baltimore | Boehringer Ingelheim |
| 9739 | David Auerbach | Assessment of cardiac electrical function and prevalence of electrocardiographic abnormalities in patients diagnosed with Dravet Syndrome and Lennox-Gastaut Syndrome | SUNY Upstate Medical University | UCB |
| 9743 | Howard Scher | Evaluating the association between radiographic progression free survival and overall survival using the ELMPC4 and ELMPC5 randomized clinical trial data | Memorial Sloan Kettering Cancer Center | Takeda |
| 9746 | María Elena Hernando Pérez | PROPHECY: Preprandial Optimized Glucose Prediction with Objective Physical Exercise andCarbohydrate Estimation for Insulin Calculation in Do-it-Yourself Systems | Universidad Politécnica de Madrid | Jaeb Center for Health Research Foundation, Inc. |
| 9748 | Ho So | Causal inference in retrospective rheumatoid arthritis clinical studies | Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong | Roche, AbbVie |
| 9764 | Wenjun Yi | Assessing the Efficacy of Trastuzumab Emtansine (T-DM1) in Human Epidermal Growth Factor Receptor 2 (HER2)+ Breast Cancer Across Varying Hormone Receptor Statuses | the Second Xiangya Hospital of Central South University | Roche |
| 9767 | Rohan Khera | A computational phenomapping approach to personalize the cardiometabolic benefits of novel glucagon-like peptide-1 receptor and glucose-dependent insulinotropic polypeptide agonists in patients with type 2 diabetes mellitus | Yale School of Medicine | Lilly |
| 9770 | Massimo Gentile | Comparison between Eloquent-3 data with real-life data | Hematology Unit of AO Cosenza | Bristol Myers Squibb |
| 9771 | Li Yang | Covariate selection and adaptive randomization for sequential experiments | Renmin University of China | Boehringer Ingelheim |
| 9774 | Aristeidis Katsanos | Individual Participant Data Meta-Analysis of Randomized Trials of Anticoagulation compared to Antiplatelet Therapy in Patients with Embolic Strokes of Undetermined Source | Population Health Research Institute, Hamilton Health Sciences Corporation | Boehringer Ingelheim |
| 9783 | Kihyuk Shin | Age-Stratified Analysis of Acne as an Adverse Event in Patients Treated with Janus Kinase Inhibitors: A Systematic Review and Meta-Analysis | Pusan National University Yangsan Hospital | AbbVie, Pfizer Inc. |
| 9787 | Hongmei Zheng | Clinical and molecular characteristics of human epidermal growth factor receptor 2-positive breast cancers: a meta-analysis | Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology | Roche |
| 9792 | maria pia sormani | Defining responders to teriflunomide treatment in Multiple Sclerosis | University of Genoa | Sanofi |
| 9793 | Lea Dousset | Immunotherapy as Prophylaxis: Exploring the Potential Impact on Hyper-Chronic Non-Melanoma Skin Cancers in Retrospective Melanoma Cohorts | Translational Research Institute, The University of Queensland, Brisbane, Australia | Bristol Myers Squibb |
| 9797 | Dr Julian Stiels | Advanced blood glucose prediction modelling | OneTwenty AG | Jaeb Center for Health Research Foundation, Inc. |
| 9809 | Emma Fröling | Systematic Review and Meta-Analysis of Adverse Events During Levetiracetam Therapy | Universitätsmedizin Charité Berlin, clincic for psychiatry and psychotherapy | UCB |
| 9811 | Derek Chu | Efficacy and safety of monoclonal antibodies in patients with uncontrolled asthma: a systematic review and network meta-analysis. | McMaster University | Roche, GlaxoSmithKline, ImmPort (a data-sharing platform funded by the National Institutes of Health), Johnson & Johnson |
| 9813 | Sameer Jauhar | Conducting a systematic review and meta-analysis to assess the incidence and severity of withdrawal symptoms following discontinuation of antidepressants | King's College London, Centre for Affective Disorders | Lundbeck, Takeda, Pfizer Inc., Lilly |
| 9815 | Tim Greten | Locoregional therapy impact on immunotherapy | Center for Cancer Research, National Cancer Institute, NIH | Roche |
| 9817 | Marco Gerlinger | To determine whether Programmed Cell Death Ligand 1 (PDL1) expression in oesophago-gastric cancer differs depending on the tumour site from which the biopsy was taken from. | Barts Cancer Institute, Queen Mary University of London | Bristol Myers Squibb |
| 9821 | Richard Franzese | Assessment of the predictive value of longitudinal circulating tumour deoxyribonucleic acid (ctDNA) dynamics for survival outcomes in non-small-cell lung cancer (NSCLC) | GSK | Roche |
| 9822 | Shuhua Yi | Clinical and molecular characteristics of Non-Hodgkin Lymphoma | Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College | Roche, Takeda |
| 9824 | Martin Okun | Using Patient-Level Data from Psoriasis Clinical Trials to Evaluate the Quantitative Relationship between Changes in Skin and Nail Psoriasis | Fort HealthCare | Lilly |
| 9826 | Lorna Wheaton | Development and application of new statistical methods for meta-analysis to evaluate treatment effectiveness and surrogate relationships in biomarker subgroups | University of Leicester | AstraZeneca, Roche |
| 9828 | Michael Bloch | Moderators and predictors of response to aripiprazole for tics in Tourette Disorder | Child Study Center, Yale University School of Medicine | Otsuka Pharmaceuticals |
| 9829 | Yuanyuan Kong | Clinical and molecular profiles of Hepatocellular Carcinoma (HCC) treated with combination immunotherapy | Beijing Friendship Hospital, Capital Medical University; Methodological Platform at the National Clinical Research Center for Digestive Diseases | Roche |
| 9834 | Tao Han | Clinical and molecular profiles of Hepatocellular Carcinoma (HCC) | The First Hospital of China Medical University | Bayer, Roche, Sanofi, Boehringer Ingelheim, NIDDK Central |
| 9835 | Yuya Matsue | Impact of serum hepcidin levels on the efficacy of daprodustat treatment in patients with chronic kidney disease | Juntendo University School of Medicine Graduate School of Medicine | GlaxoSmithKline |
| 9841 | Anke Richters | Estimating heterogeneous treatment effects of immunotherapy combination regimens for treatment of advanced/metastatic clear cell renal cell carcinoma: an individual patient data meta-analysis | The Netherlands Comprehensive Cancer Organisation | Bristol Myers Squibb |
| 9845 | Yao Zhu | Serum sodium maintenance levels and outcomes in patients with advanced prostate cancer | Fudan University Shanghai Cancer Center | Bayer, Sanofi |
| 9846 | Samantha Kleinberg | Examining Effects of Meals on Glucose in Individuals with Type 1 Diabetes | Stevens Institute of Technology | Jaeb Center for Health Research Foundation, Inc. |
| 9848 | Garrett Ash | Developing a pre-trainable foundation time series model for blood glucose prediction among people with type 1 diabetes (T1D) and then applying it to a vulnerable, understudied subset of them | Yale School of Medicine | Jaeb Center for Health Research Foundation, Inc. |
| 9863 | Yasuhiro Hagiwara | Development of Covariate Adjustment Methods to Improve Efficiency of Randomized Clinical Trials for human immunodeficiency virus infected Patients | The University of Tokyo | GlaxoSmithKline |
| 9866 | Weituo Zhang | comparing the methods of selecting and adjusting for covariates in clinical study | Shanghai Jiao Tong University School of Medicine | Lilly |
| 9870 | Alexandre Betourne | Integration of Biogen Choroideremia Data (NCT03359551 ; NTCNCT03496012) into the Rare Diseases Cures Accelerator Data and Analytics Platform (RDCA-DAP) | Critical Path Insitute | Biogen |
| 9890 | Jasmine Mitchell | The Effect of Serotonin Reuptake Inhibitors in Metastatic Colorectal Cancer | University of California, Los Angeles | Roche |
| 9906 | Alessio Cortellini | The putative role of Proton-Pump Inhibitors in patients with Basal Cell Carcinoma treated with vismodegib | Department of Surgery and Cancer Imperial College London, London | Roche |
| 9907 | Akihiro Hirakawa | Developing new statistical methodology harnessing nonconcurrent control data in infectious disease platform trials | Tokyo Medical and Dental University | Montreal Heart Institute, Lilly, NIAID (a data-sharing platform funded by the National Institutes of Health) |
| 9908 | Haitao Zhao | The clinical and prognostic features of acquired resistance to immune-checkpoint inhibitors (ICIs) in Hepatocellular carcinoma (HCC) | Peking Union Medical College Hospital | Roche |
| 9909 | John Clemmer | Improving heart failure with preserved ejection fraction (HFpEF) treatment using a mathematical model of physiology | University of Mississippi Medical Center | Boehringer Ingelheim |
| 9910 | Yang Li | Missing data considerations for patient reported outcome measures in randomized controlled trials | Renmin University of China | Pfizer Inc. |
| 9911 | Kazuki Takada | Prognosis of inoperable patients after preoperative atezolizumab administration: A post hoc analysis of Lung Cancer Mutation Consortium (LCMC) 3 | Saiseikai Fukuoka General Hospital, Fukuoka, Japan | Roche |
| 9920 | Soumyajit Roy | Does Timing of Metastatic Presentation (Synchronous versus Asynchronous) Affect Outcome in Advanced Urothelial Carcinoma? | University Hospitals Cleveland Medical Center | Roche, Lilly, AstraZeneca |
| 9924 | Thomas Büttner | Evaluation of Bellmunt Risk Score as a prognostic score in metastatic-castration resistant prostate cancer | Department of Urology and Pediatric Urology, University Hospital Bonn | Johnson & Johnson, Takeda, Sanofi |
| 9939 | Xiaoyu Yan | Organ specific tumor dynamic predict survival in patients with metastatic breast cancer | The Chinese University of Hong Kong | Roche, Pfizer Inc., Lilly |
| 9960 | Zhengfei Zhu | Organ-specific response to atezolizumab and radiotherapy in advanced non-small cell lung cancer patients: a pooled analysis | Fudan University Shanghai Cancer Center | Roche |
| 9962 | Yukinori Ozaki | Exploring risk factors and prognosis in cancer patients receiving immune checkpoint inhibitor therapy with immune-related adverse events | The Cancer Institute Hospital of Japanese Foundation for Cancer Research | Roche, AstraZeneca, Daiichi Sankyo, Inc., GlaxoSmithKline, Project Data Sphere, ONO |
| 9963 | Hanna Suominen | Develop Type 1 Diabetes Simulators/Models for Exercise in Type 1 Diabetes. | The Australian National University | Jaeb Center for Health Research Foundation, Inc. |
| 9964 | João Sérgio Neves | Effects of tirzepatide versus semaglutide on cardiovascular risk in patients with type 2 diabetes | Faculdade de Medicina da Universidade do Porto | Lilly |
| 9966 | Luis Farhat | An evaluation of lack of early improvement and later non-response in early-onset schizophrenia: a systematic review and meta-analysis of randomized controlled trials. | University of São Paulo (USP) | Johnson & Johnson, Lilly, Otsuka Pharmaceuticals |
| 10028 | Hanne Vanluchene | Development of an Inflammatory Bowel Disease (IBD) patient population dashboard to monitor and improve care through machine learning | AZ Delta | Johnson & Johnson, AbbVie |
| 10030 | Lihi Eder | Exploring Sex-related Mechanisms of Psoriatic Arthritis (PsA) response to advanced therapies (EXSEMP): Individual participant data (IPD) meta-analysis of randomized controlled trials of advanced therapies | Women's College Hospital and University of Toronto | AbbVie, Johnson & Johnson, Lilly, Pfizer Inc. |
| 10032 | Shenghong Zhang | Dynamics of Disease Activity in Monitoring Therapeutic Outcomes and Predicting Prognosis for Ulcerative Colitis | The first affiliated hospital of Sun Yat-sen University | Johnson & Johnson, Takeda |
| 10036 | Akihiro Hirakawa | Development of statistical methodology considering placebo response in randomized controlled trials targeting Alzheimer's disease | Tokyo Medical and Dental University | Lilly |
| 10037 | Shenghong Zhang | Dynamics of Disease Activity in Monitoring Therapeutic Outcomes and Predicting Prognosis for Crohn's disease | The first affiliated hospital of Sun Yat-sen University | Takeda, Johnson & Johnson, AbbVie |
| 10039 | Lena Friberg | Evaluation of dose individualization strategies in optimizing survival and patient-reported outcomes of sunitinib treatment in patients with metastatic renal cell carcinoma | Uppsala University | Pfizer Inc. |
| 10046 | Matthew Galsky | Exploring C-reactive protein (CRP) dynamics and resistance to immunotherapy in bladder cancer | Icahn School of Medicine at Mount Sinai | Roche |
| 10047 | Ramona Belfiore-Oshan | Bayesian item response theory model for the North Star Ambulatory Assessment (NSAA) rating scale | Critical Path Institute | Cure Duchenne |
| 10049 | Dag Aarsland | Neutrophil to Lymphocyte Ratio Decrease and Its Association with Clinical Changes in Late-Life Depression Treated with Vortioxetine (Lu AA21004) | King's College London | Lundbeck |
| 10052 | Yasuhiro Hagiwara | Adjusting for treatment switching in Oncology Trials: Sensitivity Analysis for Rank-Preserving Structural Failure Time Model | The University of Tokyo | Roche, Pfizer Inc. |
| 10054 | Lisa Koch | Foundational machine learning models for large scale robust modelling of continuous glucose monitoring and activity data | University of Bern Clinic for Diabetology, Endocrinology, Nutritional Medicine and Metabolism | Jaeb Center for Health Research Foundation, Inc. |
| 10055 | Christian Torp-Peteresen | Reanalyzing Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPAREG) using Longitudinal Targeted Maximum Likelihood Estimation (LTMLE) analysis. | North Zealand Hospital | Boehringer Ingelheim |
| 10090 | David Baker | Monitoring white blood cells as an indicator to assess the risks of treatment failure in multiple sclerosis | Queen Mary University of London | Biogen |
| 10091 | Jonas Saal | Establishing a risk score for Skeletal Related Events (SRE) in patients with cancer | University Hospital Bonn | Project Data Sphere, Bayer, Johnson & Johnson, Sanofi |
| 10094 | Sabatina Criscuolo | Machine Learning approach for glycemia prediction in type 1 diabetes | University of Naples Federico II | Jaeb Center for Health Research Foundation, Inc. |
| 10095 | Michael Greicius | Repurposing clinical trial data to understand potential effects of functional unblinding on efficacy of Alzheimer's drug - Gantenerumab | Stanford University | Roche |
| 10098 | Yohei Sekino | The potential prognostic value of body mass index in patients with urothelial carcinoma and renal cell carcinoma treated with immunotherapy and tyrosine kinase inhibitor. | Department of Urology at Hiroshima University | Roche |
| 10106 | mehmet fatih özbay | Exploring the Correlation between Programmed Death-Ligand 1 (PD-L1) Levels and Eosinophilia in Advanced Lung Cancer Patients Treated with Atezolizumab | Kirsehir Training and Research Hospital | Roche |
| 10112 | Alessio Cortellini | TP53 missense and truncating mutations may be linked to differential response to checkpoint blockade in patients with advanced non-small cell lung cancer: a post hoc analysis of the OAK and POPLAR trials. | Imperial College London | Roche |
| 10116 | Jean-Pierre Fauvel | Development and validation of clinical prediction tools to estimate all-cause mortality, cardiovascular and renal risk in non-dialysis chronic kidney disease (CKD) patients using machine learning | Hospices Civils de Lyon, University Claude Bernard Lyon 1 | GlaxoSmithKline |
| 10118 | Neeraj Narula | Assessing Outcomes from the EXTEND Clinical Trial Using the Modified Multiplier of the Simple Endoscopic Score for Crohn's disease (MM-SES-CD) | Hamilton Health Sciences | AbbVie |
| 10120 | Pablo Bonangelino | A Bayesian borrowing-by-parts method integrated with propensity score stratification for borrowing adult data for pediatric patients | US Food and Drug Administration | GlaxoSmithKline |
| 10121 | Itsuki Osawa | Optimized timing of empagliflozin use for cardiorenal protection: a post-hoc analysis of the EMPA-REG OUTCOME, EMPEROR-REDUCED, and EMPEROR-PRESERVED clinical trials | Columbia University Irving Medical Center | Boehringer Ingelheim |
| 10126 | Wataru Fukuokaya | Heterogeneous treatment effects of cabazitaxel in patients with castration-resistant prostate cancer | The Jikei University School of Medicine | Sanofi |
| 10137 | Mariam Khayretdinova | Predicting Placebo Response in Major Depressive Disorder on Clinical Trials Data Using Artificial Intelligence (AI)/Machine Learning (ML) on Clinical Data | Brainify.AI | Takeda, Lilly, Lundbeck, Pfizer Inc., Johnson & Johnson |
| 10138 | Issa Dahabreh | Development of statistical methods for comparison of the efficacy of anticoagulants in non-valvular atrial fibrillation | Harvard T. H. Chan School of Public Health | Daiichi Sankyo, Inc., Boehringer Ingelheim |
| 10146 | Yuki Miyai | Impact of Body Mass Index on Survival and Response in Cancer Patients Treated with Immune Checkpoint Inhibitors | Nagoya University Hospital | Project Data Sphere, ONO, Roche, AstraZeneca |
| 10151 | Anthony Willems | The Impact of Sex, Age and Race on the Immunogenicity of Meningococcal Serogroup B Vaccination in Healthy Infants, Children, Adolescents and Young Adults: A Systematic Review and Meta-Analysis | University Ghent | Pfizer Inc. |
| 10155 | Brian Gillette | Developing approaches to accelerate clinical trials using real world data (RWD) from electronic health records (EHR) | Droice Labs | Lilly, Takeda, Daiichi Sankyo, Inc. |
| 10158 | Si-Cong Ma | Biomarker-based strategies to enhance efficacy and reduce toxicity in lung cancer immunotherapy | The First Affiliated Hospital of Sun Yat-Sen University | Roche |
| 10200 | Dafne Capelusnik | Assessment of peripheral arthritis and related disease activity measurement instruments in spondyloarthritis | Care and Public Health Research Institute (CAPHRI), Maastricht University | Lilly, UCB, Johnson & Johnson, Pfizer Inc., AbbVie |
| 10204 | Yanguang Cao | Identifying Prognostic and Predictive Factors for Causal Exposure-Response Analysis of Imatinib in Treatment of Chronic Myeloid Leukemia | University of North Carolina at Chapel Hill | Pfizer Inc., Takeda |
| 10279 | Laetitia de Abreu Nunes | Examining statistical methods that leverage the hierarchical structure of adverse events for signal detection in randomised controlled trials | Pragmatic Clinical Trials Units, Queen Mary University of London | Pfizer Inc., Biogen |
| 10290 | Jeffrey Bower | Anchor Based Minimal Clinical Important Difference calculation for the Neuropathic Pain Inventory Scale | Sana Health, INC. | Pfizer Inc. |
| 10291 | Chanho Lee | Effects of ezetimibe on clinical outcomes in patient with idiopathic pulmonary fibrosis (IPF) | Yonsei University College of Medicine | Boehringer Ingelheim |
| 10293 | Joao Pedro FERREIRA | Effect of Empagliflozin on Blood Pressure in Acute Heart Failure | Faculty of Medicine of Porto University | Boehringer Ingelheim |
| 10313 | linsen ye | Effect of liver lipid deposition on the treatment of atezolizumab plus bevacizumab: a retrospective study based on the IMBrave150 | The Third Affiliated Hospital,Sun Yat-Sen University | Roche |
| 10317 | Kelley Kidwell | Seamless Design for Multiple Endpoints for Drug Development in Rare Diseases Using Gaussian Copula Model in Bayesian Framework : a case study from Hunter syndrome | University of Michigan School of Public Health | Takeda |
| 10332 | Raphaèle Seror | Retrospective validation of the Sjögren's Tool for Assessing Response (STAR) as a primary endpoint for response to treatment in Primary Sjögren's Syndrome | Immunology of Viral Infections and Autoimmune Diseases, INSERM | Servier |
| 10360 | Javier Calvo | Identifying Clinical Predictors of Weight Loss in Older Adults with Diabetes: Insights from SURPASS Clinical Trials | Universidad de Costa Rica | Lilly |
| 10381 | Neeraj Narula | Impact of Concomitant Steroid Use on Adverse Events in Ulcerative Colitis Clinical Trials | Hamilton Health Sciences | Johnson & Johnson, AbbVie, Takeda, Pfizer Inc. |
| 10390 | Aaron Mansfield | Comparison of the transcriptomic profiles of small cell lung cancer (SCLC) patients who are younger or have never smoked | Mayo Clinic | AstraZeneca |
| 10391 | You-Shan Feng | Psychometric properties and scoring approaches for the EuroQol-5 dimension-5 level (EQ-5D-5L) Psoriasis-specific questions | Universitätsklinikum Tübingen | Lilly |
| 10392 | Lorenzo Gervaso | Efficacy and safety of direct oral anticoagulants (DOACs) compared to low-molecular weight heparin (LMWH) in digestive system cancers: individual patient data metanalysis from randomized controlled trial | European Institute of Oncology (IEO) Istituto di Ricovero e Cura a Carattere Scientifico (IRCSS) Milan | Daiichi Sankyo, Inc. |
| 10403 | Andreas Meid | TREND-RIVIVAL - Trial results extension and disease course modelling for real-world evidence and valid inferences in the post-approval phase | Heidelberg University Hospital – Medical Clinic (Krehl-Klinik) Internal Medicine IX – Dept. of Clinical Pharmacology & Pharmacoepidemiology, Im Neuenheimer Feld 410 , 69120 Heidelberg | Project Data Sphere, Takeda |
| 10404 | Marco Sanduzzi Zamparelli | Effect of PPIs (proton-pump inhibitors) on treatment efficacy in patients with hepatocellular carcinoma | BCLC group, Liver Unit. Hospital Clinic of Barcelona | Roche |
| 10406 | Toby Pillinger | Physiological effects of acute antidepressant treatment in psychiatric disorders: a systematic review and network meta-analysis | King's College London (UK) | Takeda, Lundbeck, Lilly, GlaxoSmithKline, Pfizer Inc. |
| 10408 | Su Syonmez | Natural History Study of Patients With Mucopolysaccharidosis type IIIA (MPS IIIA) | Orchard Therapeutics 245 Hammersmith Road, 3rd Floor London W6 8PW United Kingdom | Takeda |
| 10411 | João Pedro Ferreira | NSAIDs use and kidney outcomes in Heart Failure | Faculty of Medicine of Porto University, Porto, Portugal | Boehringer Ingelheim |
| 10441 | Amber Salter | Examining Heterogeneity in Response to Disease-Modifying Therapy in Multiple Sclerosis | UT Southwestern Medical Center | Roche, Sanofi, Biogen |
| 10443 | Vitalay Fomin | 2024 DataWorks! Prize: Analyzing COVID-19 Drug Approval and Patient Response Using Historical Data | YAI INC. | Montreal Heart Institute, Salix Pharmaceuticals, HCor Research Institute, Certara, Hannover Medical School, Vaccines & Infectious Diseases Analytics Research Unit, Wits Health Consortium, Hospital Universitario Australia, The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, University of Washington, University of Minnesota, Johns Hopkins University |
| 10450 | Sam Royston | Merging Big Datasets for Training Blood Glucose Prediction Models | Replica Health | Jaeb Center for Health Research Foundation, Inc. |
| 10463 | Chee Lee | Meta-analysis of chemoimmunotherapy for epidermal growth factor receptor (EGFR) mutation positive non-small cell lung cancer (NSCLC) | The University of Sydney | Bristol Myers Squibb |
| 10464 | Maria Panagiotou | Blood Glucose Prediction | University of Bern | Jaeb Center for Health Research Foundation, Inc. |
| 10466 | Mia Jovanova | Temporal dynamics of lifestyle factors and glycemic control among children with Type-1 Diabetes | University of St. Gallen - School of Medicine | Jaeb Center for Health Research Foundation, Inc. |
| 10467 | Lewis Carpenter | Measurement Error in Real-World Comparative Effectiveness Studies of Progression Free Survival in Multiple Myeloma | Arcturis | Bristol Myers Squibb |
| 10469 | Shenghong Zhang | Predictors and prediction model for therapeutic outcomes in UC patients receiving Mirikizumab | The first affiliated hospital of Sun Yat-sen University | Lilly |
| 10471 | Khandan Keyomarsi | Validation of Predictive Molecular Biomarker for Predicting Response to Cyclin-Dependent Kinase 4 and 6 (CDK4/6) Inhibitors in Breast Cancer Using Data from PALOMA-2 and PALOMA-3 Studies | The University of Texas MD Anderson Cancer Center | Pfizer Inc. |
| 10475 | jiabin cai | Clinical and Molecular Characterization of Advanced Hepatocellular Carcinoma: Analysis of Therapeutic Responses Across Multiple Treatment Regimens | associate chief physician，Department of Liver Surgery and Transplantation of Zhongshan Hospital, Shanghai China | Project Data Sphere, ImmPort (a data-sharing platform funded by the National Institutes of Health), Bayer, Sanofi |
| 10486 | DongKeon Yon | Validation of Abrocitinib's efficacy and safety in moderate-to-severe atopic dermatitis across racial, ethnic, and skin type subgroups using machine learning models | Center for Digital Health, Medical Science Research Institute, Kyung Hee University | Pfizer Inc. |
| 10487 | Surya Bhatt | Response to placebo in patients with chronic obstructive pulmonary disease | RespirAnalytics LLC | Boehringer Ingelheim, AstraZeneca |
| 10492 | Yongwen Zhou | Reinforcement learning in automated insulin delivery | The third affiliated hospital of SYSU | Jaeb Center for Health Research Foundation, Inc. |
| 10495 | Jonas Saal | Investigation of the impact of serum electrolytes on the efficacy of immune-checkpoint blockade for solid cancer | University Hospital Bonn | AstraZeneca, Roche, Lilly |
| 10499 | Stefan Koudstaal | Personalized Lifetime Prediction of Survival and Treatment Benefit in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction: the LIFE-Preserved Model | Erasmus Medical Center Rotterdam, NL | Boehringer Ingelheim |
| 10511 | Min Hyuk Lim | A study of establishing Machine Learning (ML) and Artificial Intelligence (AI) models for glucose dynamics. | UNIST (Ulsan National Institute of Science and Technology) | Jaeb Center for Health Research Foundation, Inc. |
| 10540 | Alexander Drilon | Do patients with lung cancers positive for a RET gene alteration benefit from the addition of immunotherapy to chemotherapy? | Memorial Sloan Kettering Cancer Center (MSKCC) | Lilly |
| 10544 | Claire Vale | Treatment options for women with heavy menstrual bleeding: a comprehensive systematic review and network meta-analysis | University College London (UCL) | Takeda |
| 10549 | Sumayyah Patel | Cognition in Myeloma: A Systematic Review and Meta-analysis | University of Leeds | Takeda |
| 10703 | Hong Jae Chon | A validation study of a machine learning model for predicting clinical benefit in patients with hepatocellular carcinoma treated with atezolizumab and bevacizumab. | CHA Bundang Medical Center | Roche |
| 10706 | Neeraj Narula | Assessing the Impact of Disease Duration on the Likelihood of Healing in the Ileum and Colon in Crohn’s Disease | Hamilton Health Sciences | AbbVie, Takeda, Johnson & Johnson |
| 10707 | Zisheng Chen | The Association between Liver Metastasis of Non-Small Cell Lung Cancer and Prognosis Based on Immunotherapy: A Secondary Summary analysis of Individual Patient Data from Randomized Trials | The Affiliated Qingyuan Hospital (Qingyuan People's Hospital) of Guangzhou Medical University | Roche, AstraZeneca |
| 10716 | Nicholas Davies | The reduction in quality of life associated with shingles (herpes zoster): an analysis of individual patient data from multiple international studies | London School of Hygiene and Tropical Medicine | GlaxoSmithKline |
| 10717 | Alexandre Betourne | The impact of genetic variation and phenotype on lysosomal diseases, and the identification of biomarkers for disease progression and response to treatment | Critical Path Institute | Takeda, Johnson & Johnson |
| 10732 | Bryan Saunders | Semaglutide for weight loss: Where is the weight loss coming from? A systematic review and meta-analysis | University of Sao Paulo | Lilly |
| 10735 | Andrew Achaiah | Exploration of change in forced expiratory volume:forced vital capacity (FEV1:FVC) ratio from baseline to prognosticate clinical outcomes in idiopathic pulmonary fibrosis and predict treatment response to Nintedanib | Gloucestershire Royal Hospital, Gloucestershire Hospitals NHS Foundation Trust | Boehringer Ingelheim |
| 10740 | Thomas Schnitzer | Predictors of Pain Response in Knee OA | Northwestern University Feinberg School of Medicine | Lilly, Pfizer Inc., Regeneron |
| 10749 | Dennis Shung | DT1D: Digital Twin for Type 1 Diabetes | Yale School of Medicine | Jaeb Center for Health Research Foundation, Inc. |
| 10752 | Anna Maria Claudia Wägner | Exercise in Type 1 Diabetes | Fundacion canaria Institudo de investigación sanitaria de Canarias (FCIISC) | Jaeb Center for Health Research Foundation, Inc. |
| 10757 | Zhaojin Chen | Analyzing the Effectiveness of a New Cancer Treatment Using Historical Data in a Phase II Clinical Trial | Saw Swee Hock School of Public Health, National University of Singapore | AstraZeneca |
| 10765 | Konstantinos Leventakos | Gene expression profile comparisons of the immune population and the tumor subtypes in pre and post immune checkpoint inhibition (ICI) /chemo combination therapies in small cell lung cancer (SCLC) | Mayo Clinic | AstraZeneca |
| 10783 | Kathryn Connelly | Can a core set of disease activity domains define response in systemic lupus erythematosus clinical trials? An analysis of two Phase 3 randomised controlled trials of belimumab | Monash University School of Clinical Sciences | GlaxoSmithKline |
| 10785 | Jin Woo Choi | Evaluating the Efficacy and Safety of Systemic Treatments with Atezolizumab Plus Bevacizumab or Sorafenib in Patients with Hepatocellular Carcinoma and Localized Portal Vein Tumor Thrombosis | Seoul National University Hospital | Roche |
| 10786 | Yuan Huang | Jointly modeling hypoglycemic event times and longitudinal glucose measurement with Brownian motion | Yale University | Jaeb Center for Health Research Foundation, Inc. |
| 10816 | Shunan Qi | Analysis of Clinical Molecular Consistency and Treatment Benefit in lymphoma | Senior doctor, Cancer Hospital Chinese Academy of Medical Sciences | Sanofi, Takeda, Project Data Sphere |
| 10827 | Ben Cowling | Exploring Viral Shedding, Symptom Dynamics, and Antiviral Efficacy in Influenza Transmission | The University of Hong Kong | Roche |
| 10828 | Adrian Mosquera Orgueira | Machine learning predictors for chronic lymphocytic leukemia (CLL) patients obtaining benefit from the addition of obinutuzumab (O) to acalabrutinib (A) | Instituto de Investigación Sanitaria de Santiago | AstraZeneca |
| 10829 | Hollie Pilkington | Comparison of statistical methodologies for comparing metastatic renal cell carcinoma treatments | Lumanity | Pfizer Inc., Project Data Sphere |
| 10832 | Jay Park | Assessing the Potential Effect of a New Diabetes Treatment in Canadian Populations | Core Clinical Sciences | Lilly |
| 10835 | Surya Bhatt | Response to Long Acting Bronchodilators by STaging of Airflow Obstruction by the Ratio (STAR) versus Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages of Chronic Obstructive Pulmonary Disease | RespirAnalytics LLC | Boehringer Ingelheim |
| 10836 | Jean-Charles Nault | Machine learning based prediction of Survival and Progression to atezolizumab-bevacizumab in Hepatocellular Carcinoma (HCC) patients | Université Paris Cité | Roche |
| 10842 | Youqi Yang | Estimating the Effect of Tirzepatide on Body Weight in Specific Subgroups: A Secondary Analysis Across Trials | Department of Biostatistics, University of Michigan | Lilly |
| 10843 | Calvin Ke | Efficacy of Glucose-Lowering Drugs for Young-Onset Type 2 Diabetes: A Meta-Analysis of Individual Participant Data from Randomized Control Trials | University Health Network | GlaxoSmithKline |
| 10845 | Sten Deurvorst | Meta-analysis on the regional differences of cardiovascular and renal outcomes for patients treated with Sodium Glucose cotransporter 2 (SGLT-2) inhibitors | Amsterdam UMC | Boehringer Ingelheim, Johnson & Johnson |
| 10850 | Simon Cauchemez | Evaluating the impact of Baloxavir on dynamics of influenza within-host infection and within-household transmission | Institut Pasteur | Roche |
| 10852 | Ramona Belfiore-Oshan | Development of an Artificial Intelligence/Machine Learning (AI/ML) model-based clinical trial simulation platform to better characterize Loss of Ambulation in Duchenne Muscular Dystrophy (DMD) | Critical Path Institute | Cure Duchenne |
| 10855 | Stefan Leucht | Sex differences in the efficacy and tolerability of antidepressants in the acute treatment of people with major depressive disorder: an individual-participant-data, dose-response, network meta-analysis | Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, School of Medicine and Health, Technical University of Munich | Lundbeck, Lilly, GlaxoSmithKline, Pfizer Inc., Takeda |
| 10856 | Jennifer Lees | How Multimorbidity Affects Cancer Treatment: Analyzing the Impact on Treatment Safety and Effectiveness in Clinical Trials | University of Glasgow | AstraZeneca, Bayer, Boehringer Ingelheim, Lilly, ONO, Pfizer Inc., Roche, Sanofi |
| 10866 | William Phillips | A longitudinal time-based assessment of toxicity prevalence and grade of targeted therapies and chemotherapy for treatment of advanced non-small cell lung cancer | University of Ottawa | AstraZeneca, Boehringer Ingelheim, Pfizer Inc. |
| 10868 | Luke Daines | A secondary analysis of the NOVELTY study to investigate the relationship between treatable traits and health-related quality of life, asthma control, and the frequency of asthma exacerbations in adults with asthma managed in primary care | Usher Institute, University of Edinburgh | AstraZeneca |
| 10870 | Sofia Ramiro | Do fatty lesions explain why inflammation or erosions lead to new bone formation in axial spondyloarthritis (SpA)? | Leiden University Medical Center | Lilly, Pfizer Inc., UCB |
| 10916 | Shane Goodwin | Predictability of biomarkers and disease activity indices for efficacy of advanced therapies in Crohn’s disease | Western University | Johnson & Johnson, Takeda, AbbVie |
| 10939 | Lauren Meyers | Modeling the impact of antiviral for treatment on influenza attack rate in households | The University of Texas at Austin | Roche |
| 10940 | Neeraj Narula | Comparison of Onset of Efficacy of Therapies for Ulcerative Colitis Based on Patient Symptom Diary Data version 2 | Hamilton Health Sciences | Johnson & Johnson, AbbVie, Takeda, Lilly, Pfizer Inc. |
| 10954 | tianpei Hong | Sodium glucose cotransporter 2 (SGLT2) inhibitors improve islet function in patients with type 2 diabetes by reducing plasma ketone body levels | Peking University Third Hospital | Boehringer Ingelheim |
| 10956 | William Harris | Exploring the Link Between Blood Fatty Acids and Cardiovascular Health Outcomes in the STRENGTH Study | Fatty Acid Research Institute | AstraZeneca |
| 10958 | Ronghui Xu | A Novel Statistical Framework for Indirect Treatment Comparisons and Meta-analysis for validation with landmark Vedolizumab and Adalimumab trials in Ulcerative Colitis | University of California, San Diego | Takeda, AbbVie |
| 10960 | Yin Bun Cheung | Extend previously approved access at CSDR (Research Proposal 12163): Novel approaches to the modelling of protective efficacy, immunity and infectious disease incidence: Malaria vaccination | Duke-NUS Medical School, Centre for Quantitative Medicine | GlaxoSmithKline |
| 10996 | Zhi-Qiang Zhong | Heterogeneous treatment effects in Ankylosing spondylitis: an IPD meta-analysis | Shanghai Changzheng hospital | AbbVie, Johnson & Johnson |
| 10997 | Ricky Turgeon | Re-analyzing Heart Failure Treatment Outcomes Based on Patient Preferences: A Study Using Data from Multiple Clinical Trials | University of British Columbia | Boehringer Ingelheim |
| 10999 | David Cherney | Kidney Outcomes with Sodium-glucose co-transporter-2 Inhibitors (SGLT2i) in Patients with type 2 diabetes (T2D) and Atherosclerotic cardiovascular disease (ASCVD): Insights from the VERTIS-CV Study within the SMART-C Framework | University Health Network | Pfizer Inc. |
| 11001 | João Pedro Ferreira | Sodium-glucose co-transporter 2 inhibitors induced polycythemia and risk of cardiovascular events | Faculty of Medicine of Porto University | Boehringer Ingelheim, Johnson & Johnson |
| 11003 | Vitalay Fomin | Placebo effect estimation utilizing large language model | Numenos | Lilly |
| 11005 | Shane Goodwin | Disease and personal characteristics influencing the efficacy and safety of advanced therapies in moderate to severely active Crohn’s disease: Meta-analysis of individual patient data from randomized controlled trials | Western University | Johnson & Johnson, Takeda, AbbVie |
| 11010 | João Pedro Ferreira | Serum magnesium and the effect of empagliflozin in heart failure | Faculty of Medicine of Porto University | Boehringer Ingelheim |
| 11011 | Zahari Kassabov | Study of diabetes metrics during exercise to understand how to improve glycemic control in patients | Opificio Ltd | Jaeb Center for Health Research Foundation, Inc. |
| 11012 | Ali Ezzati | Predictors of Treatment Response to Acute and Preventive Medications in Migraine: Insights from the OVERCOME Study | University of California, Irvine | Lilly |
| 11018 | Iveta Jancigova | Optimizing dose-finding in early oncology trials by utilizing information from multiple measures and simulations | IQVIA | Daiichi Sankyo, Inc., Takeda |
| 11020 | Joshua Baker | Validation of Disease Activity Measurement Thresholds for Arthritis Treatment | University of Pennsylvania | Bristol Myers Squibb |
| 11038 | Andrew Strahs | Analysis of PRO-DMD-01 Functional Data to Inform Endpoints in Wave’s FORWARD-53 Study of WVE-N531 for Duchenne Muscular Dystrophy (DMD) Exon-53 Skipping Therapy | Wave Life Sciences | Cure Duchenne |
| 11041 | Alessio Cortellini | Differential effect of systemic antibiotics and proton pump inhibitors on clinical outcomes from adjuvant immunotherapy or best supportive in patients with resected early stage NSCLC (stage III): A post-hoc analysis of the Impower010 trial. | Department of Surgery and CAncer, Imperial College London (UK) | Roche |
| 11043 | George Thompson | Impact of Treatment Strategy on Candidemia and Invasive Candidiasis: A Patient Level Meta-Analysis | UC-Davis Medical Center | Astellas |
| 11046 | Nicolas Girerd | How Kidney Function Changes Before and After Hospitalization for Heart Failure: Findings from EMPEROR program | Centre Hospitalier Régional et Universitaire de Nancy | Boehringer Ingelheim |
| 11058 | Shane Goodwin | Impact of disease and patient specific factors on the efficacy and safety of advanced therapies in moderate-to-severe Ulcerative colitis: An individual patient data meta-analysis of multiple clinical trials | Western University | Takeda, AbbVie, Johnson & Johnson, Lilly, Pfizer Inc. |
| 11061 | Elias Eriksson | Post hoc patient-level analysis of the impact of paroxetine and sertraline of individual items of the Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria for premenstrual dysphoric disorder (PMDD) | Sahlgrenska Universitetssjukhuset | GlaxoSmithKline |
| 11064 | Anthony Vaccarino | Evaluating the Effectiveness of Depression Scales in Major Depressive Disorder: A Large-Scale Analysis of Clinical Trial Data | Indoc Research | GlaxoSmithKline, Lilly, Lundbeck, Takeda |
| 11065 | Felicitas Huber | Examining the Impact of Stigma in Migraine On Treatment Seeking Behaviors, Migraine Concealment, And Psychological Well-Being | Washington University in St. Louis | Lilly |
| 11067 | Samuel Maidman | A pooled analysis of all Evinacumab studies assessing the effect of the drug on lipoprotein(a) levels | Icahn School of Medicine at Mount Sinai | Regeneron |
| 11086 | Mingfang Li | Impact of Heart Failure Treatment and Empagliflozin on Stroke Risk in People with Atrial Fibrillation and Heart Failure: A Secondary Analysis from the EMPEROR-Preserved Study | The First Affiliated Hospital of Nanjing Medical University | Boehringer Ingelheim |
| 11088 | Neeraj Narula | Delayed Clinical Response to Adalimumab in Patients with Crohn’s Disease | Hamilton Health Sciences | AbbVie |
| 11090 | Alessio Cortellini | Opioid use and the efficacy of immune checkpoint blockade in patients with extensive-stage small-cell lung cancer: A post hoc analysis of CASPIAN trial | Department of Surgery and Cancer, Imperial College London (UK) | AstraZeneca |
| 11105 | Bernhard Schmidt | Comparison of major cardiovascular and kidney outcomes between women and men with chronic kidney disease receiving sodium-glucose co-transporter (SGLT-2) inhibitors | Hannover Medical School | Boehringer Ingelheim, Johnson & Johnson |
| 11120 | Sheng Luo | Identification of efficacy biomarkers associated with treatment response and survival in cancer patients to assist with personalized treatment | Duke University | Daiichi Sankyo, Inc., Lilly, Pfizer Inc., Roche |
| 11121 | James Galloway | The PARADOx (Progression Analysis in Rheumatoid Arthritis of raDiographic Outcomes) systematic review: Radiographic Progression and Treatment Tapering in Rheumatoid Arthritis | Centre for Rheumatic Diseases, King's College London | AbbVie, Pfizer Inc., UCB |
| 11130 | Joseph Doyle | Understanding the Impact of Diabetes Intervention Eligibility on Treatment Outcomes | MIT Sloan School of Management | Lilly |
| 11138 | Greg Hapgood | Assessing the Early Progression and Survival of Follicular Lymphoma Patients Compared to the General Population from the GALLIUM Trial | Metro South Health | Roche |
| 11143 | Sujin Lee | The Impact of Antibiotic Use on the Efficacy of Immune Checkpoint Inhibitors in Cancer Treatment: A Meta-Analysis | Chung-ang University | Roche, Lilly |
| 11151 | Jose Antonio Seoane | Identifying New Subgroups of Colorectal Cancer Patients with the BRAF-V600E Mutation to Improve Treatment Response Using Genetic Analysis | Vall d´Hebron Institute of Oncology | Pfizer Inc. |
| 11162 | Morgan Grams | Global Study on How Chronic Kidney Disease Affects Cardiovascular Disease Risk | NYU Grossman School of Medicine | Boehringer Ingelheim |
| 11194 | Cade Shadbolt | Tirzepatide versus placebo in adults with osteoarthritis and obesity: a secondary analysis of the SURMOUNT 1, 2, and 3 randomised trials | University of Melbourne | Lilly |
| 11201 | Sicong Ma | Markers predicting immune-related adverse events of atezolizumab in lung cancer | NYU Langone Health | Roche |
| 11206 | Jiawei Zhou | Evaluating the Impact of Cobimetinib on the Quality of Life in Melanoma Patients Using Patient Data | University of North Carolina at Chapel Hill | Roche |
| 11207 | Yipeng Zhou | Development of an AI-Driven Predictive Model for Multiple Myeloma Disease Progression and Treatment Optimization Using Chinese Real-World Data | Macquarie University | Takeda |
| 11211 | Felix Steffens | Improving Survival Predictions for Men with Hormone-Sensitive Metastatic Prostate Cancer Using the Metastasized Prostate Cancer Survival Score (MeProCSS) and Standard Treatments | University Medical Centre Mannheim | Astellas, Bayer, Roche |
| 11235 | Derek Chu | Treatment of eosinophilic esophagitis: a protocol for a systematic review and network meta-analysis of randomized controlled trials | Health Research Methods, Evidence, and Impact, Faculty of Health Sciences, McMaster University | GlaxoSmithKline, Regeneron, Takeda |
| 11236 | Jonathan Rabinowitz | Predictors of which patients will maintain symptom stability in absence of antipsychotic treatment for schizophrenia | BAR ILAN UNIVERSITY | Lilly, Otsuka Pharmaceuticals, Johnson & Johnson |
| 11246 | Paolo Napoletano | Personalized Blood Glucose Prediction Using Multimodal Real-Life Data and Artificial Intelligence | University of Milano-Bicocca | Jaeb Center for Health Research Foundation, Inc. |
| 11263 | Jacob Ollech | Identifying Factors That Predict Treatment Success in Patients with Chronic Pouchitis Using Vedolizumab | Rabin Medical Center | Takeda |
| 11264 | Alex Gordon-Weeks | Comparison of overall survival and radiologic response in patients with and without liver cancer metastasis being treated with immune checkpoint blockade | Nuffield Department of Surgical Sciences, University of Oxford | AstraZeneca, Bristol Myers Squibb, ONO, Roche |
| 11271 | Tomonori Yaguchi | Understanding the Impact of Molecular Subtypes on the Effectiveness of Kidney Cancer Treatments (Ipilimumab + Nivolumab and Sunitinib) | Kyoto University | Bristol Myers Squibb |
| 11275 | jahannaz dastgir | Analysis of functional data from Duchenne participants in a natural history study and the placebo control arm of an interventional clinical trial for the treatment of Duchenne in combination with other natural history data sets. | REGENXBIO Inc. Rockville, MD | Cure Duchenne |
| 11277 | María S Soengas | Improving Biomarker Identification for Melanoma Immunotherapy Using Ribonucleic Acid (RNA) Analysis | Fundación Sector Público Estatal Centro Nacional Investigaciones Oncológicas Carlos III (CNIO) | Bristol Myers Squibb |
| 11278 | Temiloluwa Prioleau | Comparative analysis of publicly accessible diabetes datasets | Emory University | Jaeb Center for Health Research Foundation, Inc. |
| 11281 | Carmen Castrillo | Analysis of progression on functional endpoints over time for participants in the PRO-DMD natural history database | Avidity Biosciences | Cure Duchenne |
| 11285 | Honghan Wu | Identify treatment responders in patients with type 2 diabetes using a machine learning based dynamic cardiovascular risk assessment tool (ML-CVD) in clinical trials | University of Glasgow | Johnson & Johnson, Bayer, Lilly, Sanofi, Takeda |
| 11312 | Takeo Fujii | Predictive value of Neutrophil-to-Lymphocyte Ratio in patients with Triple Negative Breast Cancer treated with Immune Checkpoint Inhibitors | Women’s Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA | Roche |
| 11325 | Seong-Keun Yoo | Development of deep learning model predicting immune checkpoint inhibitor outcomes in urothelial bladder carcinoma | Samsung Medical Center | Roche |
| 11327 | Shenghong Zhang | Predictors for therapeutic outcomes in patients with ulcerative colitis receiving Janus kinase inhibitor | The first affiliated hospital of Sun Yat-sen University | Alfasigma |
| 11328 | Katie Bechman | Effects of obesity on treatment response to Janus kinase inhibitors (JAKi) in rheumatoid arthritis | King's College London | Alfasigma, Pfizer Inc., Lilly, AbbVie |
| 11332 | Alexandre Betourne | Integration of Biogen Spinal Muscular Atrophy data into the Rare Diseases Cures Accelerator Data and Analytics Platform. | Critical Path Institute | Biogen |
| 11350 | Neeraj Narula | Modified Multiplier Simple Endoscopic Score for Crohn's Disease (MM-SES-CD) Thresholds as Predictors of Delayed Clinical Response to Upadacitinib in Patients with Crohn’s Disease | Hamilton Health Sciences | AbbVie |
| 11360 | Suzanne Hendrix | Alzheimer's Disease (AD) Placebo Data Harmonization for Future AD Data Initiative/Vivli Challenge | Pentara Corporation | Roche, Johnson & Johnson, AstraZeneca, Takeda, Lilly |
| 11369 | Neeraj Narula | Histologic Activity as a Prognostic Marker in Post-Induction Ulcerative Colitis: A Post-Hoc Analysis of the VARSITY Trial | Hamilton Health Sciences | Takeda |
| 11370 | Takaaki Maekawa | Analysis of whether Plerixafor can be used as a single agent for rapid collection of blood stem cells in advance of potential radiation exposure | National Defense Medical College | Sanofi |
| 11384 | Ana Rodríguez-Báez | Model informed drug development and precision dosing in neonates and infants (MONI) | University of Bonn, Clinical Pharmacy Institute, An der Immenburg 4,53121. Bonn, North North Rhine-Westphalia, Germany | GlaxoSmithKline, Johnson & Johnson, National Institute of Child Health and Human Development (NICHD), BioLINCC (a data-sharing platform funded by the National Institutes of Health) |
| 11425 | Neeraj Narula | Serum and Histologic Eosinophilia as a Predictive Biomarker of Response to Mirkizumab in Ulcerative Colitis | Hamilton Health Sciences | Lilly |
| 11426 | Maria Naylor | Analysis of Duchenne Muscular Dystrophy (DMD) clinical trials to inform trial design for a potential new treatment called DYNE-251 | Dyne Therapeutics | Cure Duchenne |
| 11434 | Ralph Horwitz | Understanding Variation in Treatment Response to Tirzepatide and Placebo for Weight Loss | Temple University | Lilly |
| 11436 | Ellen Prendergast | Meta-analysis of gout flare rates after stopping preventative anti-inflammatory treatment upon initiation of urate lowering therapy | University of Otago | Takeda |
| 11449 | Youssef Zeidan | Multi-Study Secondary Analysis of Radiation Therapy Outcomes in Patients with Locally Advanced or Metastatic Triple Negative Breast Cancer | Baptist Health South Florida | Roche |
| 11456 | Issa Dahabreh | Advancing methods for applying the results of clinical trials to data from medical insurance claims for patients taking anti-coagulants for non-valvular atrial fibrillation | Harvard T.H. Chan School of Public Health | Boehringer Ingelheim, Daiichi Sankyo, Inc. |
| 11465 | Ullrich O. Wenzel | Tirzepatide and Systolic Blood Pressure: An Individual Patient Metaanalysis | University Medical Center Hamburg-Eppendorf | Lilly |
| 11467 | Xiaolin Zhong | Interpretability analysis and external validation study on the efficacy inference of biologics in Ulcerative colitis (UC) patients | Affiliated Hospital of Southwest Medical University | Lilly, Takeda, Johnson & Johnson, AbbVie |
| 11487 | Gonzalo Spera | The Association between Beta-blockers and Outcomes in Triple Negative Breast Cancer | Translational Research in Oncology | Roche |
| 11544 | Ruben van Eijk | Project EVIDENCE: A living network meta-analysis of amyotrophic lateral sclerosis (ALS) clinical trials | University Medical Center Utrecht | Biogen |
| 11550 | Radboud Dolhain | Effect of Inflammation on Sperm Quality in Men with Immune-Mediated Inflammatory Diseases: A Secondary Analysis | Erasmus MC | Alfasigma |
| 11553 | Oreste Affatato | Post-hoc analysis of the efficacy of the most commonly prescribed selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) antidepressants in the prevention of depressive symptoms relapse: a pooled analysis of randomized double-blind clinical trials | University of Gothenburg | Lilly, Pfizer Inc., AbbVie |
| 11561 | JOAN BUSNER | Psychometric analysis of the Children's Depression Rating Scale-Revised (CDRS-R) in a large international study of pediatric Major Depressive Disorder (MDD) | Signant Health | Lundbeck |
| 11609 | David James Pinato | Time toxicity in patients treated with atezolizumab plus bevacizumab or sorafenib within the IMbrave 150 trial | Imperial College London | Roche |
| 11621 | Daniel Geller | Comparative efficacy and acceptability of exposure and response prevention therapy, selective serotonin reuptake inhibitors and their combinations for the treatment of obsessive-compulsive disorder in children and adolescents: a systematic review and network meta-analysis. | Mass General Brigham | Lilly |
| 11622 | Neil Vaughan | Comparison of 5 and 15 minute interval and prediction of glucose change | University of Exeter | Jaeb Center for Health Research Foundation, Inc. |
| 11639 | Jennifer Lund | Index date selection for external comparators in assessment of cancer therapies in relapsed/refractory follicular lymphoma | University of North Carolina at Chapel Hill | Roche |
| 11640 | Pierpaolo Pellicori | Effect of Empagliflozin on Neutrophil and Lymphocyte Counts, and their Ratio, in Patients with Heart Failure: the EMPEROR Program | University of Glasgow | Boehringer Ingelheim |
| 11644 | Chunquan Ou | Improving How We Analyze Recurrent Health Events in People with Heart Failure | Southern Medical University | Boehringer Ingelheim |
| 11645 | Bin Peng | Association Between Body Mass Index (BMI) and Prognosis in Cancer Patients: Analysis of Baseline, Trajectories, and Mediating Effects | Chongqing Medical University | Boehringer Ingelheim, Johnson & Johnson, Lilly, Sanofi |
| 11648 | Yohei Doi | Effects of Tirzepatide on Erythropoiesis in People with Obesity: An Individual Patient Data Meta-analysis of the SURMOUNT Trials | The University of Osaka | Lilly |
| 11649 | Neeraj Narula | Impact of Baseline Fecal Calprotectin and Histologic Activity Thresholds on Clinical and Endoscopic Outcomes in Ulcerative Colitis Trials: A Post-Hoc Analysis | Hamilton Health Sciences | Takeda, Lilly, Johnson & Johnson, AbbVie |
| 11670 | Ying Ding | Identifying subgroups and treatment heterogeneity in non-small cell lung cancer with survival outcomes. | University of Pittsburgh | Roche |
| 11672 | Sasha Klistorner | Suppression of Chronic Active Lesion Expansion as a Therapeutic Target in Multiple Sclerosis | The University of Sydney | Biogen |
| 11673 | Yoshihiro Fukumoto | Risk Factors for the Initial Decline in Estimated Glomerular Filtration Rate (eGFR) Following Empagliflozin Therapy in Patients with Heart Failure reduced Ejection Fraction (HFrEF) | Kurume University | Boehringer Ingelheim |
| 11680 | Wataru Fukuokaya | Heterogeneity of treatment effects in androgen receptor pathway inhibitors for metastatic hormone-sensitive prostate cancer | The Jikei University School of Medicine | Johnson & Johnson, Astellas, Bayer |
| 11690 | Soumyajit Roy | Training and Validation of PSA and Pain as Biomarkers and Causal Mediators in Metastatic Hormone Sensitive Prostate Cancer | University Hospitals Cleveland Medical Center | Bayer, Johnson & Johnson, Astellas |
| 11692 | Koji Kimura | External Validation of a prediction method for the individual serum concentration and therapeutic effect for optimizing adalimumab therapy in Crohn’s Disease | Tokyo University of Pharmacy and Life Sciences | AbbVie |
| 11705 | Paolo Ranzi | Prediction of glucose dynamics by Bayesian modeling | Gruppo Per l'Informatica (GPI) S.p.A. | Jaeb Center for Health Research Foundation, Inc. |
| 11718 | Kent Koster | Bacillus Calmette-Guérin (BCG) ALL-IN Meta-analysis | Texas A&M Health Science Center | Murdoch Children's Research Institute |
| 11727 | Yei Eun Shin | Amyotrophic lateral sclerosis (ALS) disease progression modeling | Seoul National University | Biogen |
| 11729 | Stefanie Hossmann | Continuous Glucose Monitoring (CGM) metrix in children | Diabetes Center Berne | Jaeb Center for Health Research Foundation, Inc. |
| 11735 | Tingyu Wen | A Deep Learning Framework for Predicting Immunotherapy Response in Lung Cancer from RNA-Seq Data | Tianjin Medical University Cancer Institute and Hospital | AstraZeneca |
| 11742 | Thomas Büttner | Bellmunt Risk Score in metastatic hormone-sensitive prostate cancer (mHSPC) | University Hospital Bonn | Bayer, Johnson & Johnson |
| 11743 | Calvin Ke | Efficacy of Glucose-Lowering Drugs for Young-Onset Type 2 Diabetes: A Meta-Analysis of Individual Participant Data from Randomized Control Trials | University Health Network | Astellas, GlaxoSmithKline |
| 11771 | Michelo Banda | Exploring the Potential of Patient-Reported Daily Symptoms to Predict Probability of Treatment Response to Disease-Modifying Anti-Rheumatic Drugs in Rheumatoid Arthritis | University of Manchester | Lilly |
| 11799 | Roberto Bernabeu-Mora | Prognostic Factors for Deterioration in Health Status, Functional Capacity, and Physical Activity, and for the Occurrence of Exacerbations in the Spanish Activity Questionnaire in Chronic Obstructive Pulmonary Disease (SAQ-COPD) Cohort of COPD Patients | Hospital General Universitario Morales Meseguer | AstraZeneca |
| 11804 | Thomas Ebert | Exploring the beneficial impact of Linagliptin on de novo chronic kidney disease (CKD) clusters in the CARMELINA trial | Leipzig University | Boehringer Ingelheim |
| 11807 | Filippo Gustavo Dall'Olio | Genomic Instability as a Biomarker of Response in Non–Small Cell Lung Cancer: Secondary Analysis of CheckMate 026 | Institut Gustave Roussy | Bristol Myers Squibb |
| 11834 | Cho Han Chiang | Association Between Empagliflozin and Risk of Venous Thromboembolism: An Individual Participant Data Meta-Analysis of Randomized Controlled Trials | The Feinstein Institutes for Medical Research | Boehringer Ingelheim |
| 11855 | Meredith Regan | Partitioned analysis of survival of patients receiving gemcitabine/cisplatin chemotherapy with or without nivolumab immunotherapy for advanced bladder cancer | Dana-Farber Cancer Institute | Bristol Myers Squibb |
| 11857 | Neil Goldenberg | Characteristics, Treatments, and Outcomes of Venous Thromboembolism in Young Adults Aged 21-40 years: Individual-Patient Meta-Analysis of Randomized Clinical Trials | Johns Hopkins University | Bayer, BioLINCC (a data-sharing platform funded by the National Institutes of Health), Boehringer Ingelheim |
| 11887 | Weiyu Ye | Predicting long-term outcomes in people with psoriasis who initially respond to systemic immunomodulatory therapy | King's College London | AbbVie, Johnson & Johnson, Lilly, UCB |
| 11908 | Stephen Balevic | Analysis of the effects of obesity on the pharmacokinetics (PK) of adalimumab in children with Juvenile Idiopathic Arthritis (JIA) | Duke University | AbbVie |
| 11912 | Alicia Kraay | Immunogenicity of the Vi-TCV typhoid conjugate vaccine and impacts on optimal vaccine policy | Gates Foundation | CVD at University of Maryland, Baltimore |
| 11916 | Kate Sutherland | Investigating biomarkers of response to immunotherapy in small cell lung cancer | Walter and Eliza Hall Institute of Medical Research | AstraZeneca |
| 11918 | Conor Judge | The Association of Finerenone Use and Cardiovascular Events in Hypertension | Ollscoil na Gaillimhe – University of Galway | Bayer |
| 11945 | Yohei Sekino | The Impact of the SETD7 gene on Outcomes in Advanced Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors | Hiroshima University Hospital | Bristol Myers Squibb |
| 11956 | Chirag Patel | Evaluating artificial intelligence approaches to forecast and interpret continuous glucose monitoring data in type 1 diabetics | Harvard University | Jaeb Center for Health Research Foundation, Inc. |
| 11960 | Yixiang Deng | Systems biology informed neural networks for glucose prediction and control in diabetes | University of Delaware | Jaeb Center for Health Research Foundation, Inc. |
| 11979 | João Sérgio Neves | Predictors of Weight Regain After Tirzepatide Discontinuation: A Post-hoc Analysis of SURMOUNT-4 | Universidade do Porto | Lilly |
| 11981 | RICARDO SANZ | Modeling of Postprandial Variability in Type 1 Diabetes Mellitus Individuals Using Artificial Intelligence Techniques | Universidad de Valencia | Jaeb Center for Health Research Foundation, Inc. |
| 11990 | David Byrne | Can network analysis be used to inform better treatment plans in anxiety and depression randomised trials? Assessing underlying assumptions and predicting treatment efficacy. | Royal College of Surgeons in Ireland | Pfizer Inc., GlaxoSmithKline, Lundbeck, Lilly, Takeda |
| 11993 | John Gregson | Advancing methods for fair outcome comparisons in clinical trials: Application to empagliflozin in heart failure using the win ratio | London School of Hygiene & Tropical Medicine | Boehringer Ingelheim |
| 11994 | Ahmad Abuhelwa | Predictors of therapeutic and adverse effects outcomes of acalabrutinib used in the treatment of chronic lymphocytic leukemia | University of Sharjah | AstraZeneca |
| 11995 | Marcus Koch | An analysis of outcome measures for the design of phase 2 futility trials in Alzheimer's Disease (AD) | University of Calgary | Lilly |
| 11996 | Jeong Il Yu | Evaluating the Effectiveness of Proton Beam Radiotherapy Combined with Atezolizumab and Bevacizumab for Primary Liver Cancer with Portal Vein Invasion: The PORTAL Study | Department of radiation oncology, Samsung Medical Center | Roche |
| 12008 | Alessio Cortellini | Impact of statin use on outcomes with darolutamide plus docetaxel in metastatic hormone sensitive prostate cancer: a post-hoc analysis of the ARASENS trial | Department of Surgery and Cancer, Imperial College London (UK) | Bayer |
| 12010 | Haitong Zhao | Impact of Baseline Adjustment Strategies on Treatment Effect Estimates in Randomized Controlled Trials: A Meta-Epidemiological and Simulation Study | West China Hospital of Sichuan University | Lilly |
| 12113 | Tengfei Wang | Unraveling Organ-Specific Response Heterogeneity and Mixed Response Patterns in Advanced non-small cell lung cancer (NSCLC): A Cross-Comparison of Real-World Evidence and Phase III Clinical Trial Data | Zhongnan Hospital of Wuhan University | AstraZeneca |
| 12436 | Alexandre Betourne | Integration of Biogen Amyotrophic Lateral Sclerosis Data into the Rare Diseases Cures Accelerator Data and Analytics Platform (RDCA-DAP) | Critical Path Institute | Biogen, Bristol Myers Squibb |
| 12442 | Joseph Geraci | Subpopulation Analysis of Melanoma | NetraMark Corporation | Daiichi Sankyo, Inc. |
| 12454 | Thomas Powles | Health related-quality of life (HRQoL) and defining immune related adverse events (irAE) in patients with renal cell carcinoma (RCC) offered adjuvant immune checkpoint inhibitor (ICI) | Barts Cancer Institute | Roche |
| 12670 | Adnan Qureshi | Risk of Recurrent Ischemic Stroke in Patients with Extracranial Vertebral Artery Stenosis: A Secondary Analysis of the PRoFESS Trial | University of Missouri System | Boehringer Ingelheim |
| 12692 | Raquel Ramos | Comparative Analysis of Chemotherapy and Epidermal Growth Factor Receptor (EGFR)-Targeted Treatment Strategies in Never-Smoker Patients with Advanced Non-Small Cell Lung Cancer | Universidade do Porto | Lilly |
| 12782 | Takashi Hosono | Magnitude and Moderators of Digital Placebo Effects on Depressive Symptoms: A Systematic Review and Meta-analysis | Regulatory Science for Pharmaceuticals and Medical Devices, School of Pharmaceutical Sciences, The University of Osaka | Otsuka Pharmaceuticals |
